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Introduction 
 
1. Hemoglobin and hemoglobinopathies 
The hemoglobin (Hb) is a globular chromoprotein (Kendrew 1962; Bianco 1998), in 
red blood cells, that deals with transportation of oxygen from the lungs to various 
tissues through the bloodstream. It is a tetramer composed of two types of 
subunits designated α and β, with a stoichiometry α2β2 (Silvestroni and Bianco 
1948; Straus, Gordon et al. 1969; Weatherall 1974). The hemoglobin consists of a 
fraction of high molecular weight, globin, and a fraction of non-protein low 
molecular weight, the heme group binding oxygen molecules in the pulmonary 
alveoli and then disposes in various tissues (Efimov 1979). Each individual heme 
molecule contains one Fe2+ atom.  In the lungs where oxygen is abundant, an 
oxygen molecule binds to the ferrous iron atom of the heme molecule. This 
interaction produces a conformational change creating a three-dimensional 
structure, where the different subunits of hemoglobin can interact in different ways 
with other subunits and neighboring molecules. 
 
Figure 1 Structure of adult hemoglobin. Hemoglobin is a globular protein consisting of two α 
chains and two β-chains . It is located within the red cells where It has the function to transport 
oxygen from the lungs to the tissues due to the presence of a prosthetic group called heme  
containing an iron ion. 
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These additional interactions determine the formation of the quaternary structure 
of the protein (Ranney HM. and Beutler E 1991; Fronticelli, Sanna et al. 1995). 
The variations in the interactions between the different subunits are trasmitted 
from the surface to the heme group of a second subunit. This cause a more 
facilitated access of the oxygen to the ion iron leading to a greater affinity of the 
haemoglobin for a second molecule of oxygen. (Figure1) (Saroff 1970). 
Defects in this protein can lead to various pathological complications broadly 
documented and characterized as hemoglobinopathies or thalassemias. 
 
1.1 Hemoglobinopathies 
The hemoglobinopathy is a genetic defect that results in an abnormal structure in 
one of the globin chains of the hemoglobin protein. The genetic defect may be due 
to the substitution of one amino acid for another eg. HbS, HbC and other altered 
hemoglobins, delection of a portion of the amino acid sequence, uncorrect 
hybridization between two chians, or abnormal elogation of the globin chian (Old 
1996; Giardine, Borg et al. 2014). The resultulting chain may be the α-chain (eg. 
HbGPhiladelphia), β-chain (eg. HbS, HbC), γ-chian (HbFTexas), or δ-chain (HbA2Flatbush) 
(Weatherall 1974). These abnormal hemoglobins may involve a wide variety of 
physiological effects, but the most severe (HbS or HbC) are characterized by 
hemolysis (Weatherall, Clegg et al. 1974).  
 
1.2 Specific Hemoglobinpathies: HbS and sicle cells disease 
The HbS gene was detected for the first time in population of native African origin. 
The incidence of the gene in this population reaches 40%, in native Afro-
Americans the incidence is 8%. Its presence, although at much lower frequency, 
was also documented in the non-Indo-European aboriginal populations of India as 
well as Middle East. In rare case have been reported in Caucasians of 
Mediterranean descent. In 1944 in Italy, Silvestroni and Bianco, submitted the first 
case in the world of β-thalassemia association with HbS, which they called micro-
drepanocytosis. In Italy, the most affected region is Sicily, where HbS is present 
with a frequency of 2-5% followed immediately by Calabria. Its’ frequency in other 
areas of Italy appears to be very low (Silvestroni and Bianco 1948). However, the 
new migratory waves from Africa and the Middle East could, in the next ten years 
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significantly change the geographical distrubution of this gene and related 
diseases (Old 1996; Patrinos, Kollia et al. 2005). 
The expression of the HbS gene is mostly present under certain populations, 
perhaps given more to climatic and environmental conditions. In fact, its 
expression in heterozygosity (sickle cell trait) represents a kind of protection 
against the infestation of Plasmodium Falciparum and reduces the severity of 
related clinical manifestations (Flint, Harding et al. 1998; Clegg and Weatherall 
1999). Unfortunately, however homozygous expression produces sickle cell 
disease characterized by a chronic hemolytic anemia and vaso-occlusive condition 
that in most cases leads to the death of the patient (Andemariam, Owarish-Gross 
et al.; Nur, Biemond et al.; Kato, McGowan et al. 2006). 
From the molecular perspective, the HbS is characterized by a point mutation 
GAG→GTG in codon 6 of the β-globin gene that results in the substitution in 6 
position on the β chain of a glutamic acid residue with one of valine (Rees, 
Williams et al.). This structural variation changes the surface of hemoglobin 
causing in deoxygenation conditions hydrophobic interaction between the 
hemoglobin tetramers, leading to the formation of polymers organized in parallel 
structures of fiber bundles (tactoids). The polymerization of hemoglobin is 
associated with significant changes in the membrane erythrocytes, which become 
less malleable and more fragile (Ballas 2002; Vekilov 2007). These alterations of 
the membrane, initially reversible, culminate with the formation in the red blood 
cells of the classical sickle form (Samuel, Salmon et al. 1990). This gives the name 
to the pathology associated with the presence of HbS, sickle cell anemia. 
Clinical manifestations associated with the presence of Hb are associated with 
different genotypes: i) homozygosity for Hb(S/S) that causes sickle cell anemia 
classic; ii) double heterozygosity with β-thalassemia (S/β such), (the form that 
most frequently found in Italy (Silvestroni, Bianco et al. 1950); iii) double 
heterozygosity with some hemoglobin variants eg. S/C, D/D Los Angeles, S/O-
Arab. The clinical demonstrations include both acute and chronic manifestations. 
In individuals homozygous for the gene Hbs, the 97% of hemoglobin is Hbs in 
childhood, the remainder being the shortest normal hemoglobin, HbA2 (α2 δ2). 
Several coexisting genetic abnormalities prevalent in African populaitons may 
ameliorate the course of the disease:  
1. α-thalassemia carriers, which comprise 20% of African Americans, have a lower 
Mean Corpuscolar Haemoglobin Concentration (MCHC) than normal individuals. It 
7 
 
has been suggested that a low MCHC produce a benefit in decreasing of the 
vasoocclusive properties of sickled cells. These sickle cell patients live longer and 
have a milder disease with respect to non-thalassemic patients (Akinsheye, 
Alsultan et al.; Steinberg 2009). 
2. Hereditary Persistence of Fetal Hemoglobin (HPFH) has established itself 
prominently in the black population. These people in the fetal hemoglobin (HbF) 
gene does not "turn off" in infancy but persists indefinitely. With the accurance of 
the HbF gene, there is a dilution of HbS, which reduces sickling in population 
(Thein, 2009) 
3. G6PD deficiency has been suggested as an ameliorative condition for sickle cell 
disease (Badens, Martinez di Montemuros et al. 2000; van Schaftingen and Gerin 
2002). This is however controversial. 
 
1.3 Thalassemia 
The thalassemia is a genetic defect that results in the production of an abnormally 
low quantity of a given hemoglobin chains (Silvestroni and Bianco 1948; Clegg 
and Weatherall 1999; Canali 2008). The defect may affect the α, β, γ, δ chain, or 
may affect some combination of thre β, γ and δ in the same patient. The result is 
an imbalanced production of globin chians and the production of an inadequate 
number of red cells. These cells are hypochromic/microcytic and contain a surfeit 
of the unaffected chains, which cannot bind the thalassemic chains in 
stoichiometrically manner (Williams Hematology Ernest Beutler 1995). These 
unrelated chains produce various kinds of damage inside the red blood cells and 
which leads to destruction of red cells within the marrow (ineffective 
erythropoiesis) and in bloodstream (hemolysis) (Cazzola 1996). 
 
1.4 Globin clusters 
To better understand thalassemia, the genes that code for the different globin 
chains should identify and characterize. 
The gene coding for the different types of globin chains present in the hemoglobin 
are organized in two groups known as globin clusters (α and β); each cluster 
consists of structural genes and some regulatory regions constituted by highly 
conserved nucleotide sequences (Bianco 1998). 
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This α-cluster of about 30 Kb is located in the distal short arm of chromosome 16 
and includes an embryonic gene (ζ), a fetal-adult block consisted of the α1 and α2 
genes although producing different quantities of mRNA, which have identical 
globin chains (Myers, Tilly et al. 1986), a few pseudo-genes (ψξ, ψα1, ψα2) and the 
θ gene, which is considered a pseudo-gene, because while producing a mRNA 
does not express any globin . 
The cluster β (or named non-α), approximately 70 kb is located in the distal portion 
of the short arm of chromosome 11and contains five structural genes ε, Gγ, Aγ, δ 
and β and the  pseudo gene ψβ (Efstratiadis, Posakony et al. 1980). The genes 
present in β cluster produce during the embryonic period the haemoglobins Gower 
I (ζ2ε2), Portland (ζ2γ2) and Gower II (α2ε2); in the fetal period HbF (α2γ2) and in the 
adult period HbA (α2β2) and HbA2 (α2δ2) (Figure2). (Lawn, Efstratiadis et al. 1980; 
Thein 2004; Thein 2005). 
The expression of the globin chains at different stages of development depends on 
the activation of several genes and them switching off through methylation and 
demethylation processes (Ho and Thein 2000; Harju, McQueen et al. 2002; 
Levings and Bungert 2002; Qiliang Li 2002). The first gene switch already 
happens at the fifth week of gestation and produce the switching off of embryonic 
hemoglobin genes in favor of the activation of fetal hemoglobin genes. In this step, 
zeta globin (ζ) gene expression decrease and the levels of alpha globins gene (α) 
increase. Alpha globins get to the maximum level at the twenty-fourth week of 
conception and remain constant throughout life. Epsilon globins (ε), instead, are 
replaced by the gamma globins (γ). The second gene switch determines a drastic 
reduction of γ-globins, which are replaced by beta-globins (β) within the first year 
of age. However, during adulthood, a small amount of γ-globins are expressed, so 
there are three types of hemoglobins: HbA (α₂β₂) that represents 97% of 
hemoglobin total, HbA₂ (α₂δ₂) and 0-2% HbF present in very low amounts. The 
HbF content depend on several factors such as age, sex and genetic 
characteristics and on the presence of point mutations in the β cluster, which could 
produce an increase of HbF (Bank 2006; Sankaran and Nathan 2010).  
The fetal hemoglobin, compared to the adult form, has greater affinity for oxygen 
and this makes it more efficient oxygen transfer from the maternal to fetal blood 
(Efstratiadis, Posakony et al. 1980). 
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In each clusters the structural genes are sorted in the same order to reflect the 
gene of expression during ontogenesis (Hanscombe, Whyatt et al. 1991). Their 
transcription is finely regulated by different protein elements (transcription factors) 
that activate or repress the globin genes through specific regulatory sequences 
placed within the globin cluster: i) promoters, ii) enhancer sequences, iii) the Locus 
Control Region (LCR). In particular the latter is located upstream of the gene for 
the ε-globin and it is able to modulate the gene transcription interacting with the 
promoters of the single globin genes. LCR region contains five domains, 
hypersensitive to DNase 1, named HS1, HS2, HS3, HS4, HS5, only the first four 
are specific to erythroid cells (Hardison, Slightom et al. 1997; Wilber, Nienhuis et 
al.). Among these the most important is certainly HS2, which performs the function 
of the enhancer or activator of transcription, it contains the binding sites for several 
transcription factors including: Sp1 (Specificity Protein 1), NF-E₂ (nuclear factor 
E2), GATA-1 (erythroid cell and megakaryocyte specific trascription factor 1) and 
USF (Upstream Stimolatory Factor) (Elnitski, Miller et al. 1997; Harju, McQueen et 
al. 2002). The domains HS3 and HS4 are involved in chromatin remodeling so as 
to facilitate the transcription factors binding. The role of HS5 is still uncertain. 
Some studies attribute to him the role of silencer or insulator (Wai, Gillemans et al. 
2003). The insulator is an element able to block the activity of the histone 
deacetylase (Hardison, Slightom et al. 1997), so LCR plays an important role in 
chromatin remodeling (Levings and Bungert 2002; Qiliang Li 2002).   
Initial studies about the regulation of the globin genes were mainly focused on the 
relationship between the LCR and the β-like genes, through the analysis of the 
function of the locus large fragments in transgenic mice (Myers, Tilly et al. 1986). 
Experiments carried out on transgenic mice, transduced with constructs containing 
both portions that the entire locus for the human β-globin gene, demostrated the 
presence of a cis-control of globin switching (Dillon, Trimborn et al. 1997). Studies 
about factors which control the globin gene expression have revealed a variety of 
activators and repressors factors that act at different stages of development. 
Unlike the LCR, the cis-acting elements play local function on neighboring regions 
of chromatin; in contrast, LCR acts on long distances to activate the expression of 
the globin genes (Dillon, Trimborn et al. 1997). These elements cis-elemnt could 
be:  
1. Silencer. It binds protein complexes interfering with the promoter activity and 
causing the reduction of gene expression (Ramchandran, Bengra et al. 2000). A 
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silencer element positioned distally in the promoter for the ε-globin gene controls 
the repression of its expression during the fetal and adult stage. The GATA1 and 
YY1 proteins constitute at least two of the components included in the repression 
complex (Raich, Clegg et al. 1995; Ramchandran, Bengra et al. 2000) In addition, 
two elements DR (Direct Repeat) in the ε-globin promoter, bind a protein recently 
identified DRED (direct repeat definitive erythroid-binding protein), which interferes 
with the factor EKLF (erythroid Kruppel-like factor) binding causing the final 
silencing of the ε-globin gene in adulthood (Nuez, Michalovich et al. 1995). 
 2. Insulator. It forms independent functional domains blocking the adverse effects 
of heterochromatin surrounding without stepping or activate gene transcription. It 
disturbs the interaction between the promoter region and other regulatory element, 
interposing between these sequences. The elements insulators can also block the 
activity of histone deacetylase. Finally, the insulators facilitate activity of elements 
enhancers located into the region of open chromatin. One hypothesis is that the 
LCR could have function of insulator, in particular, the hypersensitive 5'HS5 LCR 
site (Harju, McQueen et al. 2002). 
3. MARs (matrix attachment region) and SARs (scaffold attachment region).These 
DNA elements promote the binding to the nuclear matrix obtaining the formation of 
loops in contiguous sequences of DNA. These items can be a barrier protecting 
the locus from the effects of surrounding chromatin and impose a restriction 
structural chromatin remodeling; for these reasons, the loop of DNA could be a 
transcriptional target. The MARs have the function to protect DNA from the effects 
mediated by the elements, which act in cis in adjacent loops when the chromatin it 
widens, or have the function of keeping together with the cis-regulatory elements 
of the neighboring loops. They can also promote the juxtaposition of cis-regulatory 
elements and gene promoters in the same loop. Since the 5'HS-5 region presents 
homologies with the regions MARs can attribute this activity; this hypothesis is 
further supported by the fact that, when the LCR is positionally inverted, 5'HS5 
could isolate the globin genes by interaction with the LCR, causing the silencing of 
their expression. Although the role of 5'HS5 remains controversial, one can 
compare its function to that of a silencer element rather than insulator. 
 4. Boundary elements. They can be positioned at various levels inside the locus 
and take the limiting gene expression when associated proteins. These elements 
are characterized by some main properties: their association with insulator 
elements, the maintenance of a balance between the open and closed 
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conformation of chromatin. (Harju, McQueen et al. 2002). Multiple mechanisms of 
action have been proposed to explain the function of the LCR; the first models 
based on experiments conducted on transgenic mice, suggesting that switching 
globin happen following mechanisms of competition and the that genes proximal 
had preferential interaction with the LCR sequence. 
Currently have been proposed four different models of interaction of the LCR 
region with the different globin genes (Harju, McQueen et al. 2002). 
Looping model. LCR and regulatory elements for transcription are folded to form 
a loop interacting with the interested gene promoter. 
Tracking model. The transcription factors and cofactors bind LCR to form an 
active complex, which slides along the DNA helix, until reaching the gene of 
interest. At this point other cofactors bind the protein complex activating gene 
transcription. 
Facilitated traking model. Transcription factors bind the LCR sequence and form 
a loop which slides along the DNA until it reaches the correct gene. 
Linking model. Transcription factors in precise sequential order are arranged to 
reach the promoter region of a particular gene of interest. The chromatin structure 
is maintained in an open conformation so the different transcription factors may 
interact activating gene transcription. (Qiliang Li 2002).Below the most important 
transcription factors are reported involved in the globin expression regulation. 
(Table1) 
A possible deletion of LCR region inevitably produces an inhibition of the 
expression of all proteins encoded in the globin loci resulting in severe forms of 
thalassemia. (Curtin, Pirastu et al. 1985; Driscoll, Dobkin et al. 1989). 
The thalassemias have been described for all four chains α, β, γ, δ we will focus 
on β-thalassemia. 
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Table 1 Main transcription factors involved in the regulation of the globin genes expression 
Transcription factor Mechanism of Action Effects 
NF-E₂ 
(nuclear-factor erythroid 
derived2) 
It binds to the AP-1 domain of the 
HS2 LCR.  
It remodels the chromatin. 
GATA-1 
(Erythroid cell and 
megacaryocyte specific 
trascription factor 1)  
It binds to the promoter of ε and γ 
globin genes with activator activity. 
It binds to the region of the 
silencer ε gene in the presence of 
the protein YY1 with repressor 
activity. 
It check the process of erythroid 
cells maturation. 
 
It controls the expression of the ε 
and γ globins. 
GATA-2 
(erythroid cell and 
megacaryocyte specific 
trascription factor 2)  
Recognizes the same DNA 
sequences of GATA-1. 
It regulates the erythroid 
differentiation process. 
FOG 
(Friend of GATA1)  
It presents zinc-finger domains 
with which binds to GATA-1 
without binding directly to DNA. 
It checks the globin expression. 
NF-E₄  
(nuclear-factor erythroid  
derived 2) 
 
p22 binds to a ubiquitous 
transcription factor (CP2) recalling 
the polymerase 2. 
p14 binds to CP2 and the 
transcription factor NF-E₂ 
preventing the formation of the 
protein complex that activates γ-
globin gene transcription. 
It regulates the expression of γ-
globin gene. 
SOX 6 
(Sex Determining Region Y)-
Box 6) 
 
It binds the promoter of the y-
globin gene inhibiting the 
transcription of the latter. It binds 
to the promoter of the γ-globin 
gene only in the presence of 
BCL11A. 
It checks the maturation and 
proliferation of erythroid cells. 
FOP 
(friend of protein arginine 
methyltransferase 1)   
 
It works by reducing levels of the 
transcription factor FOP, indirectly 
increasing the levels of fetal 
hemoglobin. 
It controls the expression of γ-
globin genes. 
COUP-TF2 
(chicken ovalbumin upstream 
promoter trascription factor 
interacting protein) 
It binds to the γ-globin promoter. Represses transcription of γ-
globin gene. 
DRED-TR₂-TR₄ 
It binds to the promoter of the ε-
globin in the vicinity of a sequence 
referred to as DR. 
It is involved in silencing of the 
fetal globins. 
KLF-1 
(erythroid Kruppel-like factor) 
It binds to the CACCC sequence 
present in the β-globin gene. 
It binds to the BCL11A, activating 
gene transcription and 
consequently reducing expression 
of fetal hemoglobin. 
It checks chromatin remodeling 
and gene transcription 
It is necessary to adjust 
hematopoiesis process. 
It check γ-globin expression  
SP1 
(Specificity Protein 1)  
It recognizes and binds to GC-rich 
regions through zinc-finger motifs 
that bind to highly conserved 
regions. 
It takes part in the differentiation 
of erythroid cells processes.  
It regulates the globin switching 
process  
BCL11A 
(B cell limphomaleukemia 11A)  
In combination with other 
transcription factors, it binds to the 
γ-globin promoter.  
It regulates the expression of the 
β-globin gene and consequently 
the levels of fetal hemoglobin. 
 
14 
 
1.5 The β-thalassemia 
The β-thalassemia is an autosomal recessive disorder caused by mutations within 
and near the β-globin gene. All the mutations result in either the absence of the 
synthesis (β0-thalassemia) or reduction in synthesis (β+-thalassemia) of β-globin 
chains. (Olivieri 1999). 
The first description was written by Dr. Cooley in 1925. The name thalassemia was 
coined to reflect the geografic origin of the target population (“thalassa” is the 
classical Greek name for the Mediterranean Sea) (Haldane 1949) (Weatherall, 
Clegg et al. 1974; Weatherall and Clegg 1996). It is estimated that currently about 
1.5% of the world's population is healthy carrier (Figus, Lampis et al. 1989; 
Ristaldi, Pirastu et al. 1989). The patients are approximately 400,000 and there are 
about 60,000 new cases each year (Galanello and Origa 2010). The β-
thalassemia is present in several countries of Mediterranean, Middle east, Central 
Asia, India, Southern China, Far East as well as countries of Africa and South 
America (Figure3). The highest incidence is reported in Cyprus (14%). In Italy, the 
most affected areas are Sicily, the river Po delta and Sardinia, where there is an 
incidence of approximately 95.7% (Silvestroni, Bianco et al. 1950; Hill 1987; 
Rosatelli, Dozy et al. 1992; Canali 2008). Migration flows and marriages between 
different ethnic groups are introducing the thalassemia in new geographies such 
as North Europe (Flint, Harding et al. 1998). 
 
Figure 3 . β-thalassemia distribution. The areas with a high incidence of this disease are 
highlighted in red. In Italy stand out the areas of the Po Delta, Sardinia, Sicily and the coast of 
Southern Italy, where the incidence is very high. 
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In general, β-thalassemia can be summarized in four main clinical conditions: 
1) Thalassemia silent: this term is used to identify a condition of β thalassemia 
minor, which is hardly identified as hematological parameters and levels of HbA2 
and the HbF are almost normal in heterozygousity; it can be shown only a slight 
imbalance in the synthesis of the chains in vitro (Gonzalez-Redondo et al, 1989; 
Moi et al, 2004) 
2) Thalassemia Minor or microcytemia, also called β-thalassemia carrier or β-
thalassemia trait. It is caused by a single mutated allele (β°/β or β+/β). Clinically 
asymptomatic, patients show a slight anemia and high levels of HbA2 associated 
with increased HbF. However, in most cases, patients show clinical signs 
asymptomatic and are defined 'carriers' (Bianco 1998; Moi, Faa et al. 2004). 
3) Thalassemia Intermediate: affected individuals with significant anemia which 
does not require blood transfusions, however. This anemia is caused by 
abnormalities of both genes β, but one or both mutations are mild (β°/β or β+/β+) 
(Bianco 1998; Thein 2004). 
4) Thalassemia Major or Cooley's disease also known as Mediterranean Anemia: 
the sick people have a severe clinical presentation that implies regular blood 
transfusions. This form of β-thalassemia is caused by total lack of adult 
hemoglobin HbA. There are both mutated alleles (β°/β°, β+/β+ or β°/β+) (Thein 
2004). 
 
1.6 The β-globin genes  
The β-globin gene has a size of 1600 bp and coding for 146 amino acids. The 
gene consists of three exons (coding regions) and two introns or IVS (non-coding 
sequences) (Efstratiadis, Posakony et al. 1980; Bianco 1998). 
The general structure of the β-globin gene (Figure4) is typical of other globin loci 
and like all other globin genes consists of: 
- three exons (coding regions) and two introns or IVS ( non-coding sequences). 
- promoter region: placed upstream of the gene, essential for transcription, is 
comprised of several groups of nucleotides (box). Also, in humans there are two 
other hexanucleotide sequence located downstream of the transcription start site 
involved in the transduction of mRNA (messenger RNA). 
-  untraslated Region (UTR) present at the 5' and 3' ends. UTRs are essential for 
translation of mRNA, they are transcribed but never translated. The 3’UTR 
constitutes the region between the termination codon and the poly(A) tail. 
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cleavage of the 3’ end of the primary transcript and addition of the poly(A) tail 
which confers stability on the processed mRNA and enhances translation 
(Weatherall DJ 1991). The 5’UTR occupies a region of 50 nucleotides between 
‘cap’ site of the β-globin mRNA and the initiation (ATG) codon. There are two 
prominently conserved sequences in the 5’UTR of the various globin genes, one is 
the CTTCTG hexanucleotide found 8 through 13 nucleotides downstream from the 
cap site, and the second conserved sequence is the CACCATG, in which the last 
three nucleotides form the starting codon (Bianco 1998).  
There are more than 800 mutations (Giardine, Borg et al. 2014) in the β globin 
gene. They are mainly point mutations (involving a single nucleotide) and deletions 
(removal of gene sequence or regulatory regions) (Smetanina, Gu et al. 1997; 
Higgs 2004; Patrinos, Giardine et al. 2004; Patrinos, Kollia et al. 2005). 
Promoter mutations. In the great majority of cases there are point mutations in 
the promoter region. These kinds of mutations involve a reduction of efficiency of 
transcription. In particular, the β-globin chains are present, but much smaller than 
those produced in healthy subject (β+-thalassemia). Such changes may be 
described as "slight" (Meloni, Rosatelli et al. 1992; Rosatelli, Dozy et al. 1992).  
Non sense mutations: involve an incomplete translation, and therefore the 
production of a no functional protein. They consists in the substitution of a base in 
a DNA codon with premature stop codon generation and, thus, termination of 
translation (β°-thalassemia) (Liebhaber, Trecartin et al. 1981; Trecartin, Liebhaber 
et al. 1981). 
Frameshift mutations: consist of deletions or inserrtion of one or more 
nucleotides, which causes a shift in the reading frame of the mRNA (frameshift) 
alterating the termination of translation (Bianco 1998).  
Defects in the mRNA maturation: splicing defects and polyadenilation defects 
(Olivieri 1999). 
- Splicing mutations: they are a very large and important group of mutations 
which are responsible of a lot of β-thalassemias cases. Usually the defects consist 
in a point mutations that, with various mechanisms, alter the normal process of 
splicing. These mutations can occur either within an intron or within an exon. In the 
first case, they may cancel a regular site of splicing destroying the donor site GT or 
the acceptor site AG, reduce the efficiency of a splicing site altering its consensus 
sequence or create a new site of splicing, producing a new signal GT or AG in a 
cryptic site. When, however, mutations affecting the exons, the only thing that can 
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happen is the creation of a new donor or acceptor site of splicing, thus producing 
an abnormal mRNA (Orkin, Kazazian et al. 1982; Dominski and Kole 1993). 
- Mutations in the cut and polyadenylation site of the pre-mRNA: if the 
AATAAA sequence is mutated, the cut and polyadenilation process occurs much 
more downstream. It produces mRNA much longer (several hundred nucleotides) 
and very unstable. The resulting phenotype, in heterozygous, is a mild β+-
thalassemia with only a little lower HbA together with an increase of HbA2 
(Huisman 1997). 
Deletion of the β-globin gene: this type of mutation in β-thalassemia is quite 
rare. Individuals with this kind of mutation present hematologic characteristics very 
similar to a person with microcytemia. In these cases we can have levels of HbF 
normal or slightly higher, and a ratio α/β>1 produced by large deletions removing 
the β-globin gene, but leaving intact δ-globin gene. With few exceptions, the 
deletion usually involves the region immediately upstream of the β-globin gene 
increasing the HbA2 content (Bianco 1998). 
 
2. HPFH phenotype 
The clinical picture resulting in patients affected by β+-thalassemia or β0-
thalassemia may be improved by co-heritance of mutations related to other genes 
of the β-globin cluster (Orkin, Kazazian et al. 1982; Thein 2005). 
Particularl conditions have observed in subjects affected by hematological 
disorders with HPFH phenotype (Hereditary Persistence of Fetal Hemoglobin), 
observed for the first time in some African patients affected by sickle cell anemia 
(Thein and Craig 1998). High levels of HbF significantly improve the health status 
in patients (Thein and Menzel 2009; Galanello and Origa 2010; Cao, Moi et al. 
2011). In the HPFH condition the HbF, normally expressed at high levels only 
during the fetal stage of human development, continues to be expressed at high 
levels in adult erythroid cells. The synthesis of γ-chains in the post fetal period 
allows to recruit α-chains to perform the HbF hemoglobin (α2γ2) (Weatherall DJ 
1991). This greatly reduces the number of free alpha chains therefore decrease 
the α/non α-globin chain imbalance. In patients affected by thalassemia or other 
hemoglobinopathies, the presence of HbF reduces the severity of the disease and 
of all its related clinical complications. 
 
2.1 The γ-globin genes 
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The γ-globin genes (HBG1 and HBG2) are normally expressed in the fetal liver, 
spleen and bone marrow. The transcripts of the two γ-globin genes differ only by 
one amino acid residue in 136 position. In fact, the Glycine present in this position 
in the G-γ chain (HBG2 gene) is replaced with an Alanine in the A-γ chain (HBG1). 
The G-γ chains are the predominant transcripts at birth. 
The expression of the HBG1 and HBG2 genes, which encode the γ isoforms of 
HbF, is normally suppressed shortly before birth and replaced by expression of the 
β or δ chains, which encode HbA. Normally adults have less than 1% HbF, 
whereas the thalassemic patients and in other subjects affected by hematological 
disease, but heterozygotes for HPFH, have variable levels (5-30%) of HbF. 
Homozygotes for HPFH can express HbF in up to 100% of red blood cells (Thein 
and Craig 1998). 
The ratio of G-γ to A-γ is fairly constant (about 7:3) during the fetal period. The 
ratio decrease progressively during the postnatal γ-to-β switch, leading to an 
average value of 2:3 in the small residual amount of HbF detectable in normal 
adult blood. This switch in the γ ratio occurs together with the γ-β switch (Comi, 
Giglioni et al. 1980). Since the 60-70 years many researchers have studied about 
γ-globin genes extending the understanding of the different molecular mechanisms 
that regulating the activation, the expression and regulation of these genes. 
However, many of these regulatory mechanisms appear still unclear. 
In 2004 Li et al. have identified the minimum promoter sequence for the down 
regulation of γ-globin gene (Li, Han et al. 2004). By a series of γ promoter 
truncations the CACCC box was largely responsible for the down regulation of the 
γ-globin gene in adult erythropoiesis. The CACCC box is a common element in the 
proximal promoters of many housekeeping and lineage-specific genes. All 
mutations or deletions of this box alter the expression of the involved genes 
suggesting the CACCC box functions as a positive transcriptional element. 
 
2.2 The γ-globin gene expression 
The expression of the globin genes is regulated by several transcription factors. As 
for the β-globin genes two transcription factors, named KLF1 (Krupper-like factor 
1) and BCL11A (B cell lymphoma-leukemia 11A), have a crucial role (Armstrong, 
Bieker et al. 1998). However, BCL11A and KLF1 cooperate with numerous other 
erythroid-specific and chromatin modifiers factors to carry out their action. 
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BCL11A, also known as EV19 (Ecotropic Viral Integration Site 19) is a zinc finger 
transcription factor necessary for B lymphopoiesis and T (Liu, Keller et al. 2003). 
Several studies demonstrated that BCL11A is a negative regulator of the 
expression of γ-chains in human erythroid precursors and knockout mice 
(Sedgewick, Timofeev et al. 2008). Currently are known some BCL11A isoforms 
generated by alternative splicing. Four are the main and best characterized: 
isoform BCL11AXL (835 amino acids), isoform BCL11AL (773 amino acids), 
isoform BCL11AS (243 amino acids), isoform BCL11AXS (142 amino acids). The 
amino acids encoded by the triplets of the first three exons are the same in these 
isoforms, but they contain different carboxy-terminal end. 
BCL11AXL and BCL11AL act as repressors of the γ-globin expression in human 
adult erythroid cells (Uda, Galanello et al. 2008). BCL11A binds the upstream 
locus control region (LCR), ɛ-globin, and the intergenic regions of the β-globin 
locus, but does not results associated with the promoter of the γ-globin genes 
indicating that its regulation depends on a complex process. In fact, BCL11A 
interacts with transcription factors such GATA1, FOG1 and SOX6 and it is required 
for recruitment of the NuRD and LSD1/CoREST chromatin remodeling complexes 
to the β-globin locus in primary erythroid cells. BCL11A tied SOX6 DNA inducing 
curvature. Therefore, SOX6 may perform its function as an architectural factor by 
organizing local chromatin structure and assembling other DNA-bound 
transcriptional factors into biologically active and sterically defined multiprotein 
transcriptional complexes (Xu, Sankaran et al.; Sankaran, Menne et al. 2008; 
Sankaran, Xu et al. 2009; Sankaran and Nathan 2010). KLF1 is a member of a 
large gene family encoding erythroid-specific transcription factors, characterized 
by the presence of zinc-finger domains. The zinc fingers is an amino acid 
sequence containing four conserved amino acids including cysteine and/or 
histidine binding a zinc atom (Armstrong, Bieker et al. 1998). KLF1 binds specific 
consensus site (CACCC) on the β-globin gene promoter. Mutations in this 
sequence prevent the binding of KLF1 to the promoter and determine the 
phenotype of a mild β-thalassemia (Orkin, Kazazian et al. 1982; Moi, Faa et al. 
2004). Finally, recent studies in knockout mice for KLF1 gene and in families with 
persistence hereditary HbF (HPFH) have demonstrated that KLF1 plays a role in 
the regulation of HbF, also through an other mechanism. Studies about the 
regulation of the encoding KLF1 gene in human erythroid precursor cells carry out 
using shRNA KLF1 (short interfering RNA, RNA molecule double helix containing 
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21-22 nucleotides blocking the translation of messenger RNA target), 
demonstrated  an increased expression of the γ-globin genes associated to a 
strong reduction of BCL11A, which is an inhibitor of the γ-globin gene expression. 
In addiction, it was observed in studies carried out using specific antibody versus 
transcriptional factor lied to DNA ChIP quantitative, and playing a direct rule in the 
regulation of BCL11A expression (Zhou, Liu et al.). 
Studies of G-WAS (genome-wide association studies) identified other loci able to 
influence the production of HbF. Among these we note the region HBS1L-Myb 
located on chromosome 6q23.3. Myb is a proto-oncogene that is encoding the c-
MYB transcription factor, which plays a crucial role in erythroid differentiation. The 
absence of c-MYB in mice is lethal due to failure to develop hematopoiesis in fetal 
liver. Disruption of the HBS1L-Myb intergenic region in mice suppresses Myb 
levels and leads to elevated expression of embryonic globins and hematopoietic 
parameters similarly to human HPFH phenotype. Moreover, down regulation of 
MYB transcription factor through over-expression of microRNAs, as miR-15a and 
16-1, results in an increase of HbF levels. The HBS1L-Myb intergenic 
polymorphisms (HMIP) are present in three linkage disequilibrium (LD) blocks with 
most of the effect on HbF levels and numbers of F cells contributed by the second 
block (Thein, Menzel et al. 2007; Wahlberg, Jiang et al. 2009). 
So, to summarize, in the fetal period the expression of KLF1 is reduced in a 
manner to not be enough to stimulate for induce the β-globin gene and BCL11A 
expression (Zhou, Liu et al.). This is the typical profile of fetal β-globin gene and 
expression with low levels of β-globin and BCL11A, together with high levels of γ-
globin genes.   Similar situation occurs in the presence of molecular defects of the 
KLF1 gene. In postnatal life we observe an increase of expression of KLF,which 
determines the  activation of both the β-globin gene and BCL11A, inhibiting γ-
globin expression. 
Recent experiments carried out in CD34+ cells from patients with β-thalassemia 
transduced with shRNA versus the BCL11A mRNA showed that its silencing can 
determine a significant increase of HbF, equal to 30% of the total (Wilber, 
Hargrove et al.). In summary the pharmacological modulation of BCL11A can 
activate the production of HbF and could be represent a therapeutic approach in β-
thalassemia and sickle cell anemia. 
We can resume two potential alternatives for pharmacologically activation of HbF 
production: 
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- expression inhibition of KLF1 to reduce the of BCL11A  levels and to increase the  
HbF production; 
- gene silencing of BCL11A  to increased the expression of γ-globin genes.  
Currently here are two possible startegie for the down regulation of BCL11A. One 
involves the use of siRNA (small interference RNA). The siRNA binding to the 
target mRNA are able to degrade the mRNA reducing the gene expression and the 
protein production. Another strategy to down regulate BCL11A is using 
microRNAs, small molecules of single-stranded RNA, physiologically present in 
the cells. These molecules are able to negatively regulate the expression of 
several genes. MicroRNA binds the 3'UTR of the mRNA encoding target protein. 
This binding produces in some cases the inhibition of protein synthesis, in others, 
the mRNA degradation. In both cases there is a decrease of protein product.  
So far we have described some of the molecular mechanisms that are involved in 
the γ-globin expression. We can see as an alteration in each of these systems 
leads to a deregulation of gene expression and in this case the increase of fetal 
hemoglobin content. 
We can briefly distinguish three situations which involve increase of HbF: 
- The β-thalassemia mutation per se increase the γ-glonbin chain output. This 
occurs in the following situations: 1) δβ0-thalassemia is caused by large deletions  
in the HBB cluster; 2) deletion remove only 5’ upstream region of the HBB 
promoter, which results in high levels of HbA2. 
- Co-transmission of HPFH phenotype, which is the result of single point mutation 
in the hemoglobin Gγ (HBG2) and hemoglobin Aγ (HBG1) gene promoter. 
- Co-heritance of heterocellular HPFH phenotype linked or not linked to the HBB 
gene cluster. As we have previously described, recent studies using G-WAS have 
identified two quantitative trait loci (QTLs), BCL11A on chromosome 2p16 and 
HBS1L-MYB intergenic region on chromosome 6q23, that account 20%-30% of 
the common variation in HbF levels in healthy adults and subjects affected by β-
thalassemia and sickle cells anemia (Thein, Menzel et al. 2007; Uda, Galanello et 
al. 2008; Thein, Menzel et al. 2009). 
Higher expression of HbF is often termed 'pancellular,' whereas lower expression 
of HbF is often termed 'heterocellular’(Forget 1998). 
However HPFH phenotype can also be caused by other genetic alterations: 
- 'deletional': HPFH result from deletions within the β-globin gene cluster on 
chromosome 11p15 (Ottolenghi and Giglioni 1982; Forget 1998). 
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- 'non-deletional': HPFH result from point mutations in the promoter regions of the 
γ globin genes HBG1 and HBG2, these alterations keep intact β cluster (Forget 
1998).  
Regarding HBG1 gene about 58 mutation have been identified. Ten of these are 
particularly interesting because they are related to the HPFH phenotype. In HBG2 
gene there are about 73 mutations reported in HbVar (Giardine, Borg et al. 2014). 
Also in this case, some mutation seem to be related to the HPFH.  
These mutations occur especially in the regulatory regions at the binding sites of 
transcription factors, that are ubiquitous or erythro-specific. They alter the binding 
of the proteins to their consensus sequence and could cause an increased affinity 
for transactivating factors; an affinity reduction for transcriptional repressors, or a 
combination of the two mechanisms. Through structural studies it was possible to 
note that non-deletion HPFH point mutations are grouped in three regions of the γ- 
globin promoter. They are located close to the positions -200, -175 and -115 
upstream to transcription starting site.  The region -200, particularly rich in GC, is 
known to be the target of the different point mutations, which affect Gγ promoter in 
the position -202 (C→G) and the Aγ promoter respectively in -202 (C→T), -198 
(C→G) and -195 (C→G) positions. In vitro studies have investigated as these 
mutations influence the binding of some proteins to DNA. Indeed, mutations at 
position -202, -198, -196, -195 increase the Sp1 transcriptional factor binding 
affinity (Motum, Deng et al. 1994). In vitro experiments have shown that -175 
Aγ/Gγ point mutation prevents the binding with Otc-1 protein (Octamer Binding 
Factor 1) and modifies the binding site for GATA-1 (erythroid cell and 
megakaryocyte-specific transcription factor 1); in both cases   activating the γ-
globin gene  expression (Liu Lr and JW. 2004).  
Similar point mutations are identified in subjects with HPFH phenotype in different 
ethnic groups.  For example, the -196 (C→T) Aγ mutation was found in Sardinia 
and its association with the β039 mutation in the β-globin gene produces an F-
thalassemia. This condition presents HbF levels increase up to 10-20% by 
improving the clinical status of the disease (Galanello and Origa 2010) (Cao, Moi 
et al. 2011). 
The -117 Aγ/Gγ, -114 Aγ/Gγ mutations and a deletion of 13 bp in Aγ promoter 
involve several sites for transcription factors including the CCAAT sequence 
present in duplicate; in this case, are involved sites of different proteins: CP1 
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(poly(C)-binding protein-1), CDP (CCAAT displacement protein), GATA-1 and NF-
E3 (Nuclear Factor erytroid derived 3) (Ronchi, Bottardi et al. 1995).  
The -158 (C→T) point mutation in the Gγ promoter is known also as the XmnI G-γ 
polymorphism (rs7482144). This sequence is recognized and cut by restriction 
enzyme XmnI. This mutation is localized in Saudi Arabia and in other ethnic 
groups such as Americans and Africans. It is an example of a genetic alteration 
which is expressed only in hematopoietic stress condition. In fact, an high level of 
HbF is present in patients who have a chronic hemolytic stress condition, but it is 
completely absent in healthy parents (Thein 2005). Unlike the other non deletional 
HPFH mutations, transcription factors capable of recognizing the sequence XmnI 
are not yet known (Gilman and Huisman 1985; Labie, Pagnier et al. 1985).  
So, mutations in the HBG1and HBG2 (Table 2) promoter regions are able to 
condition several transcription factors binding involved in the HbF versus HbA 
switch, that induce HbF expression favor HPFH phenotype in the adulthood. 
Recently, G-WAS conducted on different ethnic groups, have shown the 
involvement of outside β cluster region with HbF regulation.  
Table 2 Selected BCL11A and HBS1L-MYB intergenic region SNPs 
 
 
A γ-globin gene–HBG1 
 
nd-HPFH -113 (AG) 
Georgia nd-HPFH -114(CT) 
Greek-Sardinian  HPFH -117 (GA) and IVS-I-110 
Black-Greek nd-HPFH -117 (GA) and IVSII-745 (CG) 
Cretan -158 (CT) 
Black nd-HPFH -175 (TC) 
Brazilian nd-HPFH -195 (CG) 
Italian nd-HPFH -196 (CT) 
British nd-HPFH -198(TC) 
Black nd-HPFH -202 (CT) 
Venezuelan nd-HPFH -211 (CT) 
13bp deletion (-114 -102) 
  
Gγ-globin gene–HBG2 
Czech nd-HPFH -110 (AC) 
Algerian nd-HPFH -114 (CA) 
Japanese nd-HPFH -114 (CT) 
Australian nd-HPFH  -114 (CG) 
Black nd-HPFH (XmnI) -158 (CT) 
Black nd-HPFH -161 (AG) 
Black-Sardinia-British nd-HPFH -175 (TC) 
Black nd-HPFH -202 (CG) 
-250 (C-->T) -250 (CT) 
-386 (A->G) -386 (AG) 
Iranian American nd-HPFH -567 (TG) 
25 
 
Over the years various regions were investigated but two have led to interesting 
results. It was shown that on 6q23 SNPs in the intergenic region HBS1L-Myb 
influence HbF levels. Studies in Caucasians have identified three significant SNPs. 
As for 2p16 region, in the second intron of the BCL11A gene, several mapped 
SNPs were implicated strongly in the HbF modulation. In particular three SNPs 
rs11886868, rs4671393, rs7557939 have an higher frequency in different 
populations (Sankaran, Menne et al. 2008). 
However, these SNPs often are present with a different frequency depending on 
the population taken into account. The links between SNPs and HbF has been 
amply demonstrated and validated in different groups of patients with 
hemoglobinopathies. 
For example SNPs rs28384513, rs9399137, rs4895441 (HBS1L-Myb) and 
rs4671393 (BCL11A) were identified in sickle cell anemia patients (Lettre, 
Sankaran et al. 2008), while rs 11886868 (BCL11A) was recognized as a major 
factor amiliorating the status of homozygotes β039 thalassemia patients in the 
Sardinian population (Uda, Galanello et al. 2008). (Table3) 
All aspects so far described are very interesting as they can help to clarify the 
molecular basis for the genotype/phenotype correlation and prove useful for the 
prognostic purposes. 
A polymorph framework which modulating the HbF synthesis is able to influence 
the disease clinical condition, therefore can be considered a positive prognostic 
impact element for the patient. This offers numerous reflections on possible 
therapeutic strategies for the treatment of hemoglobinopathies. 
The International HapMap Project is an organization which aims to develop a 
haplotype map (HapMap) of the human genome to describe the common patterns 
of human genetic variation. HapMap is a key resource for researchers to find 
genetic variants affecting health, disease and responses to drugs and 
environmental factors too. The information produced by the project is made freely 
available to researchers around the world (Project 2003). The International 
HapMap Project is a collaboration among researchers of academic centers, non-
profit biomedical research groups and private companies in Canada, China, 
Japan, Nigeria, the United Kingdom, and the United States. It officially started with 
a meeting on October 2002, and was expected to take about three years. 
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Table 3 Selected BCL11A and HBS1L-MYB intergenic region SNPs 
Ref SNP Origin of population (Cohort) 
BCL11A 
rs11886868 
African Americans SCD (Cooperative Study of Sickle Cell Disease 
(CSSCD), Brazil SCD, Sardinians , French β-thalassaemia 
rs4671393 
African Americans SCD (CSSCD), Brazil SCD, North 
Europeans, Chinese β­thalassaemia 
rs7557939 African Americans SCD (CSSCD), Brazil SCD 
rs6732518 
North Europeans, African Americans SCD (CSSCD), Africans 
Hong Kong β-thalassaemia heterozygotes 
heterozygotes or HbE heterozygotes, African Americans SCD , 
SCD (Silent Infarct Transfusion (SIT) Trial), Thai β-thalassaemia 
rs10189857 African Americans SCD (CSSCD), Sardinians β -thalassaemia 
rs6545816 
heterozygotes or HbE heterozygote 
Thai and Thai-Chinese β -thalassaemia/HbE, Thai β-thalassaemia 
rs7599488 African Americans SCD (CSSCD) 
rs1427407 North Europeans, Sardinians β -thalassaemia 
rs766432 
North Europeans, Chinese (Hong Kong) β­thalassaemia heterozygotes, Thai and Thai-Chinese 
β ­thalassaemia/HbE, Chinese β­ 
SCD, Hong Kong β­thalassaemia heterozygotes, African Americans 
SCD (CSSCD), Africans SCD (SIT Trial), African Americans 
thalassaemia, Thai β-thalassaemia heterozygotes or HbE heterozygotes 
rs10184550 African Americans SCD 
rs7606173 Africans SCD (SIT Trial) 
rs6706648 Africans SCD (SIT Trial) 
 
HBS1L-MYB 
rs28384513 African Americans SCD (CSSCD), Brazil SCD 
rs7776054 African Americans SCD (CSSCD) , Brazil SCD 
rs9399137 
African Americans SCD (CSSCD), Brazil SCD, North Europeans, Sardinians β
0
 
-thalassaemia ,Thai and Thai-Chinese β
0
 
-thalassaemia/HbE , French β-thalassaemia, Chinese (Hong Kong) 
β-thalassaemia heterozygotes, Africans SCD (SIT Trial) 
rs9389268 African Americans SCD (CSSCD), Brazil SCD 
rs4895441 
African Americans SCD (CSSCD) , Brazil SCD , Sardinians, 
Sardinians β -thalassaemia, Thai and Thai-Chinese β - 
thalassaemia/HbE, North Europeans, Chinese β-thalassaemia, 
Africans SCD (SIT Trial), Chinese β-thalassaemia heterozygotes 
rs6929404 North Europeans 
rs9402686 
African Americans SCD (CSSCD) , North Europeans , Chinese β- 
thalassaemia 
rs1320963 North Europeans 
rs6904897 North Europeans, Sardinians β -thalassaemia 
rs35959442 Chinese β­thalassaemia 
rs9376090 North Europeans ,Chinese β-thalassaemia 
rs4895440 North Europeans, Chinese β-thalassaemia 
rs9494142 Chinese β­thalassaemia 
rs9402685 North Europeans, Chinese β-thalassaemia 
rs11759553 North Europeans, Chinese β-thalassaemia 
rs6934903 Chinese β­thalassaemia heterozygotes  
 
 It comprises two phases, the complete data obtained in Phase I were published 
on October 2005. The analysis of the Phase II dataset was published in October 
2007. The Phase III dataset was released in spring 2009. 
27 
 
Galarneau et al. (2010) resequenced 175.2 kb to fine map HbF association signals 
at the BCL11A, HBS1L-Myb and β-globin loci investigated in 190 individuals 
including the HapMap European CEU, Nigerian YRI founders and 70 African 
Americans with sickle cell anemia. The authors discovered 1489 sequence 
variants, including 910 previously unreported variants. Using this information and 
data from HapMap, Galarneau et al. (2010) selected and genotyped 95 SNPs. The 
XmnI polymorphism rs7482144 in the proximal promoter of HBG2 marks the 
Senegal and Arab-Indian haplotypes and is associated with HbF levels in African 
Americans with sickle cell disease (Lettre et al., 2008). Galarneau et al. 2010) 
replicated the association between rs7482144 and HbF levels. p=3.7x10(-7). 
However, rs10128556, a T/C SNP located downstream of HBG1 (rs142200), was 
more strongly associated with HbF levels than rs7482144 by 2 orders of 
magnitude (p=1.3x10(-9). When conditioned on rs10128556, the HbF association 
result for rs7482144 was not significant, indicating that rs7482144 is not a causal 
variant for HbF levels in African Americans with sickle cell anemia. The results of a 
haplotype analysis of the 43 SNPs in the beta-globin locus using rs10128556 as a 
covariate were not significant (p=0.40), indicating that rs10128556 or a marker in 
linkage disequilibrium with it is the principal HbF-influencing variant at the beta-
globin locus in African Americans with sickle cell anemia.  
 
3. The hematopoiesis and erythroid cell methods of culture. 
The cells forming the blood have a short relatively lifetime, for this reason, the 
human body contains systems to ensure a continuous cell turnover. The 
hematopoiesis is the process of production of all blood cells from stem cells pluri-
potent and it takes place, in the adult, in the bone marrow. The site of 
hematopoiesis varies in different stages of our life. The bone marrow is about 5% 
of total body weight and it is distributed mainly in the flat bones and long in 
childhood and youth, while in later life you it happens at the level of the ribs, 
vertebrae, sternum and pelvis. During intrauterine life the hematopoiesis happens 
instead, first in the yolk sac and then in the liver and spleen, while from 7-8 months 
of gestation, the hematopoiesis occurs gradually in the bone marrow in special 
areas called "niches" represented by 1-2% of the population bone marrow.  
As the site of erythropoiesis changes the process regarding the red cells 
production, the globin genes being expressed also change, progressing from 
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embryonic to fetal and finally to adult (Figure5). Thus, globin gene regulation 
serves both as a model for developmental gene regulation during ontogeny and for 
the molecular mechanism playing a role in cellular differentiation (Pope, Fibach et 
al. 2000). 
 
Figure 5 Hemopoiesis. All lymphoid and myeloid cells are originated from a single multipotent 
hematopoietic stem cell. At the bottom are represented the steps leading to the formation of a 
mature red blood cell.  
 
Hematopoietic stem cells are also found in the blood, but in very low percentage, 
approximately 0.05% of peripheral blood cells (Isgro, Marziali et al. 2009). 
Hematopoietic stem cells are characterized by the presence of specific antigens 
located on the cell surface. In particular, the CD34+ antigen identifies all 
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hematopoietic stem cells and bone marrow progenitors; this is a transmembrane 
glycoprotein of 110 kDa single chain; the presence of many glycosylation sites, the 
lack of tyrosine kinase activity and the very low frequency of synthesis and 
degradation suggests that CD34+ is a receptor involved in cell-cell or cell-
extracellular matrix interaction. His expression varies with the degree of 
differentiation and proliferative potential of hematopoietic cellular elements: it is 
highest in the most primitive population of the bone, represented by the "long-term 
culture-initiating cells" (LTC-IC), and it is thought that it is lost gradually during the 
cell proliferation and differentiation. This marker is expressed by 1-3% of the cells 
of the bone, from 0.01-0.1% of peripheral blood cells and by 0.1-0.4% of the cells 
of the umbilical cord (Isgro, Marziali et al. 2009). One of the first steps of 
differentiation of hematopoietic stem cells is to continue the path of differentiation 
in myeloid or lymphoid sense. Together they will give rise to all blood cells. Stem 
cells still have the capacity to divide, but which are not able to differentiate along 
all the different ways and guide its development only to a specific line are defined 
hematopoietic committed, these cells are intended for differentiation according to 
one line of differentiation. They proliferate in differentiating morphologically 
identifiable precursors, which are subject to greater maturity, through which 
acquire the functions highly specialized and lose their ability to regenerate yourself 
(Amit and Itskovitz-Eldor 2006). The latter, in their turn, give rise to cells that can 
differentiate further producing (Gurdon, Byrne et al. 2003) myeloblasts, from which 
they originated granulocytes; erythroblasts, from which derive reticulocytes, and 
then the red blood cells; megakaryocytes, from which are formed platelets. The 
process of the differentiation, and in particular the specialization of cells is made 
possible by a system of gene regulation that repressing the not specific-genes of 
that cellular sector. Gene regulation is ensured by chemical signals internal to the 
same cell and by signals from outside the cell, for example from adjacent cells. 
The early stages of the hematopoietic process are controlled by a group of growth 
factors called cytokines, produced and secreted not only by the marrow cells, but 
also by cells of the immune system. Among the cytokines mainly involved in the 
differentiation process are the SCF (stem cells factor), interleukin-3, GM-CSF 
(Granulocyte-macrophage colony stimulating factor). Then there are growth factors 
such as EPO (erythropoietin) which acts on already specialized cells. EPO binds 
to protein receptors with tyrosine kinase activity activating a mechanism of 
phosphorylation of the target proteins (Box et al., 1996). The whole process 
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leading to the production of erythrocytes starting from stem cells is called 
erythropoiesis. This process requires in addition to the presence of cytokines and 
erythropoietin and the presence of folic acid, vitamin B₁₂, iron and trace elements 
such as copper, cobalt and nickel too. 
The first erythroid-committed progenitors are defined functionally as burst-forming 
units (BFUe) (Clarke and Housman 1977). They can be isolated from bone marrow 
and peripheral blood. The BFU-E can be maintained in culture and after 10-15 
days give rise to colonies of erythroid precursors. Erythroid units colony-forming 
(CFU-E) are more mature cells, capable of producing of small dimensions cellular 
clones. The formation of erythrocytes from the committed cells is regulated by the 
EPO that interacting with specific receptors present on the membrane of 
committed cells and leads to the formation of precursor said pro-normoblasts (also 
called pro-erythroblasts). The time required for this process is usually about a 
week (at least four cell divisions) and during this period occurs the reduction the 
size of the nucleus and the increase in the synthesis of hemoglobin (Cuneo, 
Balboni et al. 1994). Following the last cellular division, the nucleus is pyknotic 
ousted from erythroblast and in this way, creates the reticulocyte. Reticulocytes 
remain for about two or three days in the bone marrow and then be placed in the 
blood circuit, where they assume their final morphology (loss of mitochondria and 
ribosomes). After 24 hours the erythrocytes take a structure similar to biconcave 
and oval disks with a diameter of about 6-8 uM and a maximum thickness of 2 uM, 
is totally free of cellular organelles and has the ability to transfer large amounts of 
gas (especially oxygen and CO₂) facilited by ratio between surface and volume. 
The developmental aspects of erythropoiesis have been studied in culture using in 
vitro established cell lines that can be induced to express erythroid characteristics, 
or using primary cultures of cells derived from progenitors present in the bone 
marrow or in peripheral blood. 
Erythroid cell lines have been used extensively as models to study β-thalassemia 
and to develop new therapeutic strategies. In addition, primary cultures of 
erythroid cells can be readily established from a lot of normal and individual 
patients and their growth in vitro forming blackberries. Until today, the erythroid 
cells were cultured either in semi-solid medium, where they develop into discrete 
colonies, or in liquid medium where they grow as single cells or clusters in 
suspension (Fibach, Manor et al. 1989) (Leimberg, Konijn et al. 2003) (Fibach and 
Prus 2005). In all these systems erythropoietin (EPO) is essential for full 
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development of hemoglobin containing erythroid cells (Fibach, Bianchi et al. 2003). 
Here will be describe these two cellular culture systems. 
Semi-solid cultures. This method permit to evaluate the quantity and quality of the 
grown progenitors, but theis immobilization in the semisolid medium results in 
several disadvantages that make it technically difficult to carry out quantitative 
analyses of the developing cells. The culture of erythroid precursors performed in 
this manner could be provide for suspension of single hematopoietic cells, derived 
from bone marrow, peripheral blood or from other sources, such as the fetal liver, 
cord blood or neonatal spleen adults, and are dispersed in semi-solid media 
usually containing methyl cellulose or plasma clot. With this method it's possible to 
study the colonies grown from a single cell in vitro. Colonies begin to appear after 
3-4 days of incubation, and reach their final size and haemoglobinization after 1-2 
weeks. Each colony is a clone derived from a progenitor erythroid-committed. On 
the basis of the final size of the colonies and the time required for theircan be 
distinguished hemoglobinization various types of progenitors. The colony forming 
units erythroid late (CFUe) reach the final size and hemoglobinization after 1 week 
and then disappear, while the early erythroid burst-forming units (BFUe) develop 
after 2 weeks. Erythroid colonies can be distinguishes from other (myeloid) 
colonies by their red colour or by their positive reaction with heme-specific 
reagents. The fact that in this culture system the cells are immobilized in semi-
solid medium results in several disadvantages. The cell yield per colony and the 
total cells per culture are low making it technically difficult to carry out biochemical, 
molecular and immunological characterizations of the  developing cells. Also, it is a 
one-step continuous culture and addition of the tested agents during the culture is 
difficult. In addition, the HbF produced in colonies grown in semi-solid medium is 
significantly higher than that produced in vivo by the same donor of the cells 
(Fibach, Bianchi et al. 2003).  
The two-phase liquid cultures. The culture procedure yields populations that are 
large, relatively pure, and synchronized (in terms of differentiation), and which 
mimic in vivo erythropoiesis. Since the cells are grown in suspension, samples of 
cells can be remuved every time without disturbing the cultures and assayed for 
various parameters, e.g., morphology, size, number, viability, apoptosis, cell cycle, 
surface antigens, and gene expression. Cultures can be initiated with cells derived 
from a whole unit of blood obtained from normal donors (or polycythemia patients 
undergoing phlebotomy). The starting material, i.e., the “buffy-coat” fraction, is 
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readily available, since it is routinely separated and discarded by the blood bank 
during preparation of packed red blood cells (RBC) and platelet-rich plasma. 
Anemic patients commonly show high frequencies of erythroid progenitors; 
cultures from anemic patients (e.g., thalassemia, sickle cell anemia) are usually 
initiated with cells taken of 20 ml as blood sample. 
Peripheral blood cells are employed in this procedure for the following reasons: (a) 
the availability of peripheral blood; and (b) the homogeneity of the peripheral blood 
erythroid progenitors, namely early BFUe (Clarke and Housman 1977), as 
opposed to bone marrow, which contains progenitors at various developmental 
stages. 
The culture procedure is divided into two phases is been described from Fibach. 
The first is an EPO-independent phase, where peripheral blood mononuclear cells 
are isolated and cultured in liquid medium supplemented with conditioned medium 
derived from the 5637 human bladder carcinoma cell line and cyclosporine that 
killing lymphocytes, helps to select the erythroid progenitor cells. This conditioned 
medium contains a variety of growth factors, not including EPO (Myers, Katz et al. 
1984). During this phase, early erythroid-committed progenitors, called burst-
forming units erythroid (BFUe), proliferate and differentiate into colony-forming unit 
erythroid (CFUe)–like progenitors. After one week in phase I, the cultures contain 
some adherent cells (mainly macrophages) and nonadherent cells (mainly 
lymphocytes). The nonadherent cells are harvested, washed and cultured in fresh 
phase II medium supplemented with EPO. In the absence of necessary cytokines 
to support their proliferation and differentiation, nonerythroid progenitors stop their 
development. As these cells multiply, they form clusters, then large aggregates 
reaching hundreds of cells. When these cells are addresed to differentiation, they 
decrease in size and accumulate hemoglobin, and the aggregates assume a 
reddish color. The globin expression in the maturing erythrocyte during the two-
phase system mimics expression patterns, which occurs in ontogenesis with the 
fetal to adult hemoglobin switch. This is seen in the reciprocal relationship between 
γ- and β-globin gene expression, in which γ-globin content declines together a β-
globin increasing in early phase II and then amount high levels in late phase II. As 
expected, α-globin also reaches maximum expression when total hemoglobin 
increases in the late stage (Pope, Fibach et al. 2000). This culture system has 
been used extensively for screening and studying drugs that can modulate the 
production of hemoglobins, in particular HbF (Fibach 2001). The distribution of the 
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cultured erythroid cell population, with respect to intracellular Hb, such as HbF can 
be analyzed by flow cytometry using monoclonal antibodies directed against 
specific Hb subtypes (Amoyal, Goldfarb et al. 2003). The Hb content of the 
cultured cells can be quantified by HPLC analysis (Huisman 1987). The globin 
mRNA can be quantified by various techniques including reverse transcription and 
real-time quantitative polymerase chain reaction (RT-PCR) (Fibach et al., 2003).  
Given the importance of human hematopoietic stem cells (hHSCs), research is 
developing methods and land for their expansion and maintenance, aimed at their 
use in the medical field (Watanabe, Kawano et al. 1999).Good results can be 
obtained with cells derived from other sources, includind CD34+ cells purified by 
immunomagnetic bead technologies. 
Hematopoietic stem cells (HSCs) are isolated from peripheral blood by means of 
particular methods (such as the method MACS), able to recognize and select the 
receptor CD34+ located on the cell membrane, allowing the exclusion of 
monocytes, macrophages, and of most of the lymphocytes and other cell types 
(Zuccato, Breda et al.; Watanabe, Kawano et al. 1999; Wang, Hsu et al. 2001). 
Starting from a peripheral blood sample of about 20-25ml, the two methods, 
successive and complementary, are applied to obtaining a cell culture as much as 
possible pure. The Ficoll Hypaque, is used to "separate" lymphocytes, 
macrophages, fibroblasts and erythroid precursors from the remaining blood’s 
cellular component; the MACS method (Magnetic Activated Cell Sorting), which 
allowed us to obtain a population of CD34+ cells as pure as possible (80-90%). In 
this step the cells are incubated with magnetic microbeads having on their surface 
small structures similar to receptors able to bind CD34+ cells. Years ago several 
groups of researchers are developing various innovative protocols aimed at 
optimizing the selection of CD34+ cells and their expansion ex vivo. In 1998 Malik 
et. al. had described a system for culturing erythroid precursors starting from an 
enrichment of CD34+ cell (Malik, Barsky et al. 1998). Other important contributions 
were made to the field over the last 20 years by different groups who have 
developed a cocktail of factors containing stem cell factor (SCF), erythropoietin, 
and dexamethasone named SED, that can be used to induce extensive 
proliferation of a subset of erythroid progenitors (Carotta, Pilat et al. 2004; Dolznig, 
Kolbus et al. 2005; Leberbauer, Boulme et al. 2005). Olivier et al. recently has 
presented evidence that the SED cocktail could be used to induce proliferation of 
CD34+ cells derived from hESCs (Olivier, Qiu et al.). In particular the last years by 
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Breda et al. has been proposed a different composition of the culture medium 
which represents a modified version of the medium developed by Leberbauer 
(Breda, Casu et al.2012; Leberbauer, Boulme et al. 2005). This medium provides 
that the isolated cells are maintained in two different types of culture medium. It is 
composed of a serum-free StemSpan  containing bovine serum albumin (BSA), 
hunam recombinant, insulin and human transferrin (iron-saturated), 2-
Mercaptoethanol, Iscove's Modified Dulbecco’s Medium. At the medium is added a 
cytokine cocktail (Flt-3 Ligand, stem cell factor, IL-3, IL-6), EPO, dexamethasone 
and 1% penicillin and streptomycin. As described by Breda et al. in 2012, the 
advantage production of this method has is a huge number of undifferentiated 
CD34+ cells that can be employed to different application i.e frozen, thawed, 
infected for gene therapy. The CD34+ cells in this condition continue slowly their 
multiplication process reaching the maximum level of expansion after about 10 
days maintaining the cells at a concentration of about 1x106 cells/mL. If it's 
possible to control the status of erythroid differentiation. Several experiments have 
shown that maintaining the cells in close contact, reduces the time required for 
erythroid differentiation. After these 10 days the cells can be frozen (de Sio, Naldini 
2009; Wang, Hsu et al. 2001) or used for experiments. At this point the cells that 
are still at a level of undifferentiation are transferred into phase II medium 
containing α-modified essential medium supplemented with 30% fetal calf serum 
and 10-5M β-mercaptoethanol. Also in this step it must be used erythropoietin to 
stimulate erythroid differentiation. This protocol expansion and freezing of CD34+ 
cells has been developed by (Breda, Casu et al.). To carry out the experiments of 
gene therapy with β-thalassemia lentiviral vector AnkT9W. Although the cells have 
undergone a shock temporary post thawing, it was possible to evaluate the 
increase of HbA following the lentiviral vector treatment.  
The ability to cryopreserve different rates of CD34+ cells derived from a single 
subject is a very tempting prospect for the entire scientific community. Have 
available rates of frozen cells harvested from patients affected by hematological 
disease, stimulates researchers to look more and more innovative applications to 
take advantage of these resouces to seal the deal it increasingly and help to 
renforce  the core concept for developing 'ad personam' therapy. 
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4. Therapeutic approaches for β-thalassemia and sickle cell anemia 
The hemoglobin disorders are an inherited genetic diseases, characterized by the 
reduction (β+-thalassemia) or absence (β0-thalassemia) of the β-globin chains in 
adult hemoglobin (Silvestroni and Bianco 1948; Clegg and Weatherall 1999). The 
shortage of β-globin chains is combined with an α globin chains free accumulation, 
this causes a red blood cells premature death in the bone marrow defined as 
'ineffective erythropoiesis'. The rapid destruction of red blood cells is associated 
with splenic enlargement and skeletal changes. In fact, the bone marrow is 
subjected to an abnormal work to try to compensate the red blood cells loss. The 
many scientific advances aimed at the discovery of new therapeutic strategies 
have greatly improved the expectations and the life style of patients affectd by 
hemoglobin disorders.  
In summary, we can identify three typologies of therapeutic approach shown 
below. 
 
4.1 Definitive therapies 
We find in this group some therapies aimed at solving the disease permanently 
including bone marrow and umbilical cord blood cell transplantation. About bone 
marrow transplantation (BMT), the first successful BMT for thalassaemia major 
was performed in 1982 and now over 1500 transplants have been performed 
worldwide with the most experience from Pesaro, Italy (Lawson, Roberts et al. 
2003). Just in Pesaro, in 1989, following analysis of potential negative factors such 
as low quality of chelation therapy before the transplantation, the marked 
hepatomegaly and portal fibrosis, were established three classes of risk, in which 
splitting transplant patients and according to them, several protocols of action were 
developed (Lucarelli, Galimberti et al. 1998). Clearly, the essential prerequisite to 
make bone marrow transplantation is the availability of a compatible donor. After 
an ablative treatment of immunosuppression the patient is ready to be 
transplanted by infusion of bone marrow into a peripheral vein (Lucarelli, Andreani 
et al. 2002). Early after transplantation may occur rejection of organ 
transplantation. In this case the patient thalassemia will again be subject to 
undergo transfusion therapy. Another adverse event post transplantation is the 
appearance of a disease known as graft versus host disease (GVHD), which can 
occur in acute and chronic. In both cases, complications can occur in different 
anatomical areas leading to death (Robbins 1997). In this type of therapy it should 
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not be overlooked the harmful effects produced bydisease in the body patient 
before transplantation. The best outcome of transplant will have in enough young 
patients (Lucarelli, Andreani et al. 2002). However, often after the transplant it's 
necessary to put the patients to procedure of chelation therapy to remove all the 
iron overload in the vital organs. The patients can not be subjected to this 
treatment, can be treated with subcutaneous infusions of deferoxamine (Lucarelli, 
Andreani et al. 2002). 
 
4.2 Maintenance therapies 
As the term maintenance, this class of treatments tries to balance the clinical 
effects produced by the disease, but not solve them completely. 
(i)Trasfusion therapy 
 With transfusions, its provides the amount of hemoglobin required to perform all 
body functions. The transfusions allow reduce the bone marrow expansion, the 
bone alterations and limit the spleen activity. Unfortunately, various drawbacks to 
the blood transfusion are correlated, both in terms of compatibility and safety (risk 
of viral infections such as the B and C hepatitis and HIV virus), but also with 
regard to the significant quantities of introduced iron (about 200-250 mg every 200 
ml of transfused red blood cells) in the body causing toxicity due to formation of 
reactive oxygen species.In the body there are tissues having a high number of 
receptors for transferrin and those NTBI (not trasferrin bound iron) such as liver, 
heart and endocrine organs; transfused thalassemia patients are subjected to iron 
chelation therapy To limit this damage. In addition in some cases it is necessary 
performe surgical procedure as splenectomy. Unfortunately, often this leads to a 
weakening of the immune system, exposing patients to infections sometimes of 
severe entity. 
(ii) Iron chelation therapy 
Deferoxamine (Desferal®), patented drug in the ‘70s, is able to mask the six 
coordination sites of the iron. It is administered subcutaneously or intravenously, 
and has a 'short half-life in fact infusions are sustained for 8-12 hours, with the use 
of an infusion pump constant. This drug is not able to cross the cell membrane and 
binds iron only in the blood and bile. The chelated iron is excreted equally in urine 
and stool (Schrier and Angelucci 2005). In recent years, new iron chelators, orally 
active, were developed. Among these drugs, the most used is deferiprone 
(Ferriprox®), theoretically it has the potential to be more effective than 
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deferoxamine in removing intracellular iron from some tissues (Piga, Gaglioti et al. 
2003; Shalev, et al. 1999). Moreover, a comparative study of the effects of the two 
chelators (deferiprone and deferoxamine) on survival and cardiac complications, 
showed greater activity of deferiprone on deposits of iron in the heart, thus 
improving the conditions of the organ. This action was attributed both to the ability 
of this molecule to enter into the cells and to its longer half-life and the opportunity 
to make an uninterrupted therapy (seven days a week), with more frequent doses 
(three per day) than that achieved with deferoxamine (Piga et al, 2003). It’s 
possible to do combined therapy between deferoxamine and deferiprone, because 
they act synergistically respectively at cardiac and hepatic levels. The last 
generation (2007) of iron chelator drug is the Deferasirox (ICL670, Exjade®). It is 
taken orally with a single daily administration (Cappellini 2005) and has a high 
effectiveness  reducing side effects with a relative long circulating half-life of 8 to 
16 hours and documented cellular permeability. 
Another method tolimit the amount of iron transfused is the “therapeutic 
erythrocytapheresis”. A certain volume of blood containing a mix of both young and 
senescent erythrocytes is picked up to the patient. This is replaced with the same 
volume of blood from the donor, in which they were selected only the younger 
cells. In this manner, the cells survive for longer in the body of the transfused 
patient and there will be no direct transfer of senescent cells preventing a further 
iron accumulation in the spleen. 
(iii) Drug therapies for the increase the erythroid differentiation and HbF induction. 
Since a long time the properties of different molecules, natural or synthetic, are 
investigated about their ability to simulate the erythroid differentiation. Some of 
these molecules are already widely employed for the β-thalassemia and sickle cell 
anemia treatment, others there are in clinical trials. Furthermore, as reported in 
previous chapters, we have described as the switch from HbF to HbA ends in the 
sixth month of the child's life, but traces of HbF persist during adulthood (Rodgers 
and Saunthararajah 2001). Studies on patients with HPFH phenotype (High 
Persistence of Fetal Hemoglobin) has led to suggest an hypothetical new 
therapeutic approach based on the possibility to increase the γ-globin chains and 
HbF synthesis to compensate the deficit of adult hemoglobin in the anemic 
patients. An HPFH phenotype has been demonstrated that could make 
thalassemia patients less dependent by blood transfusion therapy and improves 
the overall clinical picture (Zuccato, Breda et al. 2012). In the Table 4, are 
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reported, the main molecules employed for induction of the erythroid differentiation 
and the expression of HbF, classified on the basis of the mechanism of action. We 
reported some examples in the following list of compounds. 
 
Table 4 Principal HbF inducers and their mechanisms of action  
INDUCERS MECHANISM OF ACTION 
Hydroxyurea Ribonucleotide-reductase inhibitors 
5-azacytidine DNA hypomethylation 
Cytosine-arabinoside (ara-C) DNA hypomethylation 
Butyrate Histone deacetylase inhibitor 
Tricostatina A (TSA) Histone deacetylase inhibitor 
Apicidine Histone deacetylase inhibitor 
Rapamycin, Everolimus Protein-binding inhibitor 
Mithramycin DNA-binding inhibitor 
Cisplatin and derivates DNA-binding inhibitor 
Chromomycin, Tallimustine, Distamycin DNA-binding inhibitor 
Angelicin DNA-binding inhibitor 
Resveratrol Antioxidants 
Erythropoietin Hormone 
 
a) Hypomethylating agents 
Methyl-transferase inhibitors act on DNA hypomethylation, this mechanism 
cancels the downregulation of the synthesis of γ-globin chains. Already in 1982 it 
was observed that the 5- azacytidine, a cytotoxic drug, administered in mice 
stimulated an increase in HbF production. The drug was in clinical trials, but its use 
in therapy it is somewhat difficult due to possible carcinogenic effects. The 5-
azacytidine and its less toxic harmful analogue 5-aza-2'-deoxycytidine (decitabine) 
were administered to β-thalassemia patients and the results were an increase of 
HbF (Curtin, Pirastu et al. 1985). 
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Another hypomethylating molecule with effect erythro-differentiating widely used in 
various cancer therapies is cytosine-arabinoside (ara-C). This drug works has a 
short plasma half-life but also to suboptimal concentrations it is able to induce a 
robust erythroid differentiation (Kufe DW 1985; Cortesi, Gui et al. 1998). To reduce 
the toxic effect it is often associated with retinoids (Cortesi, Gui et al. 1998). 
b) Histone deacetylase inhibitors  
It is now known as the histone deacetylase enzymes are responsible of the DNA 
wrapping and gene silencing. Studies on some molecules able to inhibit histone 
deacetylases have been shown to induce gene transcription. Butyrate and other 
compounds with small chains of fatty acids induce HbF inhibiting through histone 
deacetylase (Little, Dempsey et al. 1995). Butyrate-responsive elements (BRES) 
have been identified not only in the γ-globin promoter, but also in other genes 
(Glauber, Wandersee et al. 1991; Pace, Li et al. 1996). The effect of butyrate in the 
treatment of β-thalassemia patients seems to be optimal when the drug is not 
administered consistently (Perrine, Ginder et al. 1993; Sher, Ginder et al. 1995). 
Other histone deacetylase inhibitors (HDAC) molecules are the Trichostatin A 
(TSA), an organic compound that serves as an antifungal antibiotic and Apicidin, a 
drug with antiproliferative action adopted in different cancer therapies. For these 
molecules are reported an ability to induce the HbF expression (Pufahl, Katryniok 
et al.; Witt, Monkemeyer et al. 2003). 
c) Ribonucleotide-reductase inhibitors 
Hydroxyurea is a myelosuppressive drug used for the treatment of various 
leukemias. This drug used in hemoglobin disease, has been shown to increase 
levels of HbF in a fairly satisfactory (Bradai, Abad et al. 2003; Alebouyeh, 
Moussavi et al. 2004; Watanapokasin, et al. 2006). The Hydroxyurea is used for its 
power to modify enzymes HDACs, which allows bone marrow cells to express 
again the γ-chain of HbF, however this drug has exhibited some cytotoxicity and  
transient effects and rather unpredictable. 
d) DNA-binding molecules 
Several drugs binding DNA in a sequence-specific manner have been identified. 
These molecules alter the binding of transcription factors to the promoter region 
silencing or activating the gene located downstream. Experiments in vitro on K562 
erythroleukemia cells and on erythroid precursors have demonstrated how the 
chromomycin (Bianchi, Osti et al. 1999), tallimustine (Bianchi, Chiarabelli et al. 
2001), the cisplatin and derivatives (Bianchi, Ongaro et al. 2000), analogs of 
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distamycin are able to stimulate an induction of erythroid differentiation and an 
increased HbF production (Bianchi, Chiarabelli et al. 2001). Additionally, other in 
vitro experiments have highlighted an increases of γ-globin mRNA accumulation 
and fetal hemoglobin (HbF) production following treatment with angelicin, an 
organic molecule of natural origin belonging to the furocoumarins family (Borgatti, 
Chilin et al.; Lampronti, Bianchi et al. 2003). In the category of drugs which bind 
DNA we find also mithramycin (Bianchi, Osti et al. 1999; Fibach, Bianchi et al. 
2003) a very toxic antibiotic initially used exclusively as antineoplastic,  but 
appears to be a a putative interesting molecules in the treatment of β–thalassemia, 
if use at low concentrations(Lozzio and Lozzio 1975; Fibach, Bianchi et al. 2003). 
e) Protein-binding drugs 
Rapamycin is an antibiotic its targeting a serine threonine kinase (mTOR, 
mammalian Target Of Rapamycin), which regulates the growth, proliferation, 
motility and cell survival. Several new cancer drugs are targeted to inhibit this 
enzyme. In particular, rapamycin binds the intracellular receptor FKBP12, inhibiting 
the mTOR signaling pathway. This mechanism induces a powerful effect on 
erythroid differentiation without inhibitis the proliferative activity of the cells. (Lozzio 
and Lozzio 1975; Rutherford and Harrison 1979; Gambari, del Senno et al. 1984; 
Mischiati, Sereni et al. 2004). On the same signaling pathway also acts 
Everolimus, a structural analogue of rapamycin with very low toxicity (Zuccato, 
Bianchi et al. 2007).  
f) Antioxidants 
We have seen in previous chapters as in thalassemia patients there is a extremely 
harmful iron accumulation. The overload of this metal in the body induces a strong 
oxidative stress. Resveratrol is an antibiotic naturally produced by several plants 
able to fight oxidative stress by reducing free radicals. It’s been still conducted 
several studies on the numerous properties of this molecule, but it has already 
been demonstrated its ability to prolong the red blood cells life  and to induce HbF 
production (Bianchi, Zuccato et al. 2009; Fibach, Prus et al. 2012), because the 
Resveratrol is easy available on the market it is necessary to play attention to the 
care do it yourself. 
g) Hormones 
Erythropoietin or EPO is a glycoprotein hormone produced by the kidneys in 
humans and to a lesser extent by the liver and the brain, which has as its primary 
function the regulation of erythropoiesis (production of red blood cells by the bone 
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marrow). The EPO was also produced in the laboratory and used as a drug to treat 
anemia in patients with kidney disease, blood diseases, and to allow a faster 
recovery after the administration of chemotherapy in cancer patients. The 
administration of EPO to β-thalassemia patients induces the synthesis of γ-globin 
during the maturation of erythroid precursor cells and, then the increase of HbF 
(Breymann, Fibach et al. 1999). 
 
4.3 Gene therapy 
Gene therapy has as its aim the care of a genetic defect, by using a DNA fragment 
containing the nucleotide sequence of the "correct" gene as a therapeutic agent. 
This concept has been applied in humans for the treatment of various genetic 
diseases, using molecular and cellular conbination therapies to "correct" DNA in 
the target cell by restoring the expression of the defective gene. In particular, the 
genetic strategies for the treatment of hemoglobinopathies, especially β-
thalassemia and sickle cell anemia provide for the restore of the correct adult 
globin chains. For the achievement of this purpose could be proposed different 
experimental approaches. 
a) The gene transfer 
The gene transfer into hematopoietic stem cell is a technique widely used in 
animal models and, also, is present in clinical trials for several genetic diseases. 
It’s possible use cells taken to the patient in order to eliminate all the problems 
related to the HLA compatibility. This strategy has four strengths: 1) the transfer of 
the single gene in specific hemopoietic stem cell, 2) the endogenous expression of 
the transgene at high levels, 3) the maintenance of the expression over time and 
4- the use of not pathogenic vectors.  
Initially to avoid the problems associated with the pathogenicity of the virus have 
been also tested non-viral vectors. Examples could be naked DNA, cationic lipid 
binding DNA through electrostatic interaction, and particles of condensed DNA. All 
these methods have proved ineffective for in vivo transfection; furthermore, the 
gene transfer results in transient expression of genes of interest. 
The virus-mediated gene transfer seems to be more effective. After several 
approaches (eg. adenovirus, oncoviruses (Stathopulos 2003) was reached to the 
use of lentiviruses. The lentiviral vectors derived from HIV-1 and other lentiviruses 
have attracted great interest for their ability to transduce cells not actively dividing. 
They can transduce a broad spectrum of target cells, including neurons, retinal 
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photoreceptors, dendritic cells, macrophages, hepatocytes, and hematopoietic 
stem cells (HSCs). Another very important element is to be attributed to the 
lentivirus genome stability and to the good packaging capacity (Sadelain, Lisowski 
et al. 2005; Sadelain, Boulad et al. 2008). Has been also shown that incorporating 
in the lentiviral vector some LCR elements, it could be optimized the transgene 
expression (Sadelain, Lisowski et al. 2005). Some researchers have managed to 
obtain a new lentiviral construct containing the β-globin gene, the promoter 
sequences, enhancers and a proximal region comprising the elements LCR, 
including HS2, HS3 and HS4 sites. One of this vector is called TNS9 (Rivella, May 
et al. 2003). Using the TNS9 vector, the Sadelain’s group have first demonstrated 
efficient gene transfer in bone marrow hematopoietic stem cells, tissue-specific 
transgene expression and long-term correction in a mouse model of β-thalassemia 
intermedia (Sadelain, Riviere et al.). Numerous studies concerned with identifying 
the incorporeted components into the lentiviral vector to guarantee a high, stable 
and robust expression. The element that has proved most effective is the insulator 
named cHS-4 from the chicken β-globin LCR, thanks to its ability to isolate the 
coding sequence by the influences of the surrounding chromatin. Moreover, the 
insulators have the additional aim to avoid the insertional oncogenesis, depending 
on the random integration of foreign genetic material, whether of viral or non-viral 
origin. This effect has been demonstrated in mouse models. A more recent study 
shown that a lentiviral vector expressing the human β-globin gene under control of 
its regulatory elements and flanked by chromatin insulator elements upon 
integration into host hematopoietic cells,  has produced: (1) transduction at hight 
level on bone marrow progenitor cells from four patients,  with transfusion-
dependent thalassemia major, (2) complete phenotypic and functional correction of 
the in vitro model of human thalassemia erythropoiesis, (3) levels of β-globin 
similar to that derived from normal bone marrow progenitors, and (4) effective 
human erythropoiesis with circulating β-globin-producing human erythroid cells in 
genetically corrected xenografts, at levels comparable to normal bone marrow 
xenograft controls (Malik and Arumugam 2005). The successes achieved in mouse 
models in the treatment of sickle cell anemia and β-thalassemia intermedia have 
prompted researchers to further improve lentiviral vectors for gene therapy. It was 
constructed a new Lenti-Globin vector containing a β-globin gene nemed βA -
T87Q, that produces HbβA-T87Q,  which can be easily discriminated from normal 
hemoglobin as it has a mutation in codon 87 (Thr→Gln) of β-globin gene. This 
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vector contains a deletion in region 3'LTR and can function as SIN vector (self-
inactivating); β-LCR elements; chicken cHS4 insulator elements which prevent the 
activation of genes adjacent the insertion (Rivella and Sadelain 1998).This vector 
is in Phase II clinical trial. 
Ten patients (5 with β thalassemia and 5 with sickle cell anemia) were treated with 
this system by the Dr.Leboulch team in Paris (Bank, Dorazio et al. 2005; Bank 
2006). A further lentiviral vector has been developed on the basis of the vector 
TNS9. This construct called T9W contains: a promoter of cytomegalovirus (CMV) 
in 5', a self-inactivating deletion in 3'-LCR, post-transcriptional regulatory elements 
of the hepatitis virus (WPRE) located in cis. Some years ago, starting from the 
structure of the vector T9W it was built a new lentiviral vector, named AnkT9W, 
which carries the human β-globin gene both erythroid-specific ankyrin 5-'hyper-
sensitive (HS) barrier insulator. (Imren, Fabry et al. 2004; Breda, Casu et al. 2012). 
The ankyrin elements allow stable integration of the transgene avoiding post-
transcriptional changes. The vector AnkT9W in CD34+ cells produced a significant 
increase of the HbA synthesis also, it was highlighted a correlation between 
increase of the HbA and integrated VCN (vector copy number). In the animal 
model AnkT9W showed a good improvement of β-thalassemia phenotype (Breda, 
Casu et al. 2012).  
b) The antisense strategies 
This is another type of gene therapy which allows the correction of the mRNA 
processing and can be used only with a particular set of mutations, referred top 
splicing sites. The antisense strategy is using oligonucleotides to modulate the 
transfer of informations from gene to protein altering RNA intermediate metabolism 
. It is possible to produce two different results depending on the type of 
oligonucleotide used and the target sequence recognized: gene silencing or 
through mRNA processing alteration. One key point of the mRNA molecules 
metabolism is the excision of introns, this reactions are specific for junction 
sequence and require the concerted action of many proteins, forming the 
splicesoma complex. Antisense oligonucleotides binding to the regions necessary 
for the junction can prevent the binding of factors required or physically prevent 
the cut reaction. Therefore, this implies, inhibition of mature mRNA production. 
Many researchers try to correct the effect of mutations using oligonucleotides, 
causing aberrant splicing to restore the normal gene function The oligonucleotides 
used to modify splicing are different from those used in silencing. In particular, they 
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should not activate RNase H, in fact this destroys the pre-mRNA target before 
being spliced, and should be able to compete effectively with splicing factors of 
access to the primary messenger, contained in the cell nucleus (Sazani and Kole 
2003). Early studies, in which antisense oligonucleotides have been used to 
modulate splicing have provided for the use of these molecules to correct aberrant 
splicing of pre-mRNA of β-globin, caused by mutations in thalassemic disease 
(Dominski and Kole 1993). Another possible use of oligonucleotides can be the 
regulation of alternative splicing, stimulating or inhibiting the production of a variant 
protein (Mercatante, Sazani et al. 2001) and also the stimulation of the exon 
skipping, where the oligonucleotides can be used for promoting a process of 
alternative splicing, which avoids the inclusion of an exon defective in a mature 
mRNA. 
c) Gene targeting strategies 
The oligonucleotides used in the gene targeting strategy able to correct point 
mutations, include those that use triplex-forming oligonucleotides, RNA/DNA 
hybrid oligonucleotides (chimeraplasty) and small DNA fragments (SDFs), which 
are used in the small fragments homologous replacement (SFHR) strategy. The 
SDFs are composed of either single-strand (ssDNA) and double-strand DNA 
(dsDNA). These SDFs effect homologous exchange between incoming SDF 
sequences and endogenous (genomic or episomal) sequences resulting in 
phenotypic changes (Gruenert 2003). Gene targeting is the only procedure that 
can produce predefined alterations in the genome of eukaryotic cells. As such, 
gene targeting is an attractive approach to gene therapy of genetic diseases, 
because it can lead to the accurate correction of the defect in the target locus of 
interest. Also, this type of gene therapy it is not restricted by the size of the 
mutated gene, but the damaged portion need to be considered. Real correction of 
the defective gene should permanently block the genetic disease by restoring the 
normal production of the protein product; the corrected gene is under the control of 
its own regulatory sequences, and this avoids the problems related to a gene 
expression. Another element in favor of gene targeting is the limitation of the risk 
associated with an insertion mutation in proximity to an oncogene (Yanez and 
Porter 1998). 
However in some cases have been observed some appeared mutations resulting 
from gene targeting. A potential disadvantage of gene correction using this method 
is the need to know the location and type of mutation to be corrected, and may 
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require the use of different therapeutic DNA for different patients presenting the 
same disease. While presenting numerous advantageous conditions, the biggest 
problem related to the use of gene targeting is its low transfection efficiency 
(Yanez and Porter 1998). 
d) Read-through strategy.  
This therapy approach is based on the continuation of mRNA translation to 
ribosomal level. Some patients are affected by a nonsense mutation leading to the 
production of a premature stop codon. This event produces a truncated protein 
(PTC) (Dominski and Kole 1993; Rivella and Sadelain 1998) (Salvatori, Breveglieri 
et al. 2009) (Salvatori, Cantale et al. 2009). Good results have been achieved in 
the treatment of mouse models and cell diseases such cystic fibrosis, Duchenne 
muscular dystrophy and hemophilia, doing hypothesize its use in the treatment of 
β-thalassemia, particularly in relation to mutation β039 (Altamura, Castaldo et al. 
2013). Several molecules have been tested to verify if they could induce the PTC 
suppression, but those that were found to be the best have  low molecular weight, 
in particular they belong to aminoglycoside antibiotic class. There are several 
human trials that are giving a positive outcome following treatment with 
aminoglycosides. These molecules have been an increase in the translation of 
mRNA containing PCT. Among the different aminoglycosides, appears to be the 
most used geneticin named G418. The general mechanism of PCT suppression   
by aminoglycosides is not completely clear, but it’s known that their bactericidal 
effects as antibiotics, are due to inhibition or alteration of translation during the 
protein synthesis process. To date, the G418 is used both to conduct the in vivo 
experiments (Yang, Feng et al. 2007) and in vitro, for example as a reference 
molecule to test the read-through activity of other similar compounds (McElroy, 
Nomura et al.) and taken as model for the study and development of new 
aminoglycoside compounds exhibiting less side effects (Jung, Ku et al. 2011). For 
induction of the read-through will still use other aminoglycosides such as 
gentamicin and tobramycin. About the β-thalassemia, it must be considered that 
the most prevalent mutation is in Italy, a nonsense mutation, with a percentage of 
70%, among affected persons, it’s the β°39 mutation (Rosatelli, Dozy et al. 1992). 
In addition, there are many other stop mutations causing β-thalassemia in the 
world, So it’s important to identifymolecules ever more effective and able to 
produce a lasting effect of correction with  the stop mutation. 
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e) Ribozyme 
A little hint talking about gene therapy should be made regarding the use of 
ribozymes. These molecules bind and degrade a specific gene transcription 
product. It has managed to achieve specific ribozymes for suppression of α-globin 
chains mRNA. The RNA degradation of this kind of globin-chain is a strategy to 
reduce the precipitation of α-globin tetramers thatcause serious damage to the 
erythroid precursors and could be very dangerous worsening for the clinical picture 
of thalassemia (Shen, Ikonomi et al. 1999). 
f) Using of iPSC in cellular therapy Embryonic stem cells (hESCs) are pluripotent 
cells derived from ICM (Inner Cell Mass), can differentiate into several cellular 
types and, as  result of injection into blastocysts, they can give rise to all tissues 
obtained from the three germ layers(mesoderm, endoderm and ectoderm) (Arora 
and Daley; Maekawa and Yamanaka; Fischbach and Fischbach 2004). 
Embryonic stem cells could be used for the treatment of several serious diseases 
(congenital or acquired) such as Parkinson's disease, leukemia, 
hemoglobinopathies and spinal cord injury (Fischbach and Fischbach 2004). 
However, there are a number of ethical issues on the use of embryonic cells. 
One way around these problems is the generation of pluripotent cells directly from 
adult somatic cells, (which are cell differentiated) of the patient and executing one 
trans-transplant. These cells are called iPSC (induced pluripotent stem cells) and 
are pluripotent stem cells artificially generated and derived from a non-pluripotent 
cell (Arora and Daley; Okita, Yamakawa et al.). To date, several studies suggest 
that embryonic stem cells (hESCs) and induced pluripotent stem cells are very 
similar in many aspects, such as the expression of certain genes, the framework of 
promoter methylation and expression of specific markers for stem cells, the 
potential of differentiation (Arora and Daley 2012). 
The first induced pluripotent stem cells (iPSCs) were generated in 2006 by 
Yamanaka et al, who used viral vectors (such as retrovirus and lentivirus) to 
transduce mouse fibroblasts using genes, which was found to be associated with 
stem cells and their pluripotency. Using different genes combinations Yamanaka 
concluded that the four key genes for the production of pluripotent stem cells were 
Otc-3/4, Sox-2, c-Myc and Klf-4. In fact, the crucial point is the amount of 
transcription that these genes are able to "produce" (Arora and Daley 2012; 
Maekawa and Yamanaka 2011). 
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Before you can use the iPSC such as cell therapy, it is necessary to differentiate 
them in the type of cells that we want to be able to perform a transplant. In the 
contest to develope a therapy for hemoglobinopathies, the usable cells could be 
the hematopoietic stem cells.To try this therapeutic approch it must be considered 
several issue: 
- the way to obtain a sufficient number of hematopoietic stem cells to be 
transplanted starting from iPSC from (Watanabe, Kawano et al. 1999; Prelle, Zink 
et al. 2002). 
- the difficulty of maintaining these cells in culture (Amit and Itskovitz-Eldor 2006). 
- must be pay very attention to crop timing, because hematopoietic stem cells are 
not an immortalized line, but they undergo hemopoietic  
These cells are really a great therapeutic resource, but the only limiting factor 
derived by the lack of the absolute Certainly that they generated the desired 
differentiated cells; in fact the iPSC could differentiate the back leading to 
generation of other specific kind of cell To the need to be absolutely Certain That 
These cells, once injected into the patient, give rise only to the Desired cell type. 
g) Gene editing strategies 
In recent years, is catching on an other kind of therapeutic genetic approach: the 
genomic engineering. The genome engineering exploits the natural mechanisms 
that the cell has for DNA repair in order to induce permanent changes in the target 
genome. So, the researchers must try to mimic the creation of a damage in the 
DNA double helix at the position where they want to introduce a change. When the 
genomic DNA is damaged, the cell tries to repair the damage by activating 
mechanisms that ensure the integrity of the genetic heritage of the cell. Usually, 
two mechanisms are used: non-homologous end joining (Lieber 2008) and 
homologous recombination (Kass and Jasin 2010). The first mechanism is active 
throughout the cell cycle, but it can induce mutations. The second is only active in 
the S and G2 phases when the chromatid brother is used as a mold to correct the 
DNA damage in a very precise way (SanFilippo J 2008). The mechanism non-
homologous end joining can create mutations, adding or removing nucleotides, in 
the moment in which the two DNA ends are welded. Therefore, the researcher can 
use this mechanism to the targeted inactivation of a gene or by entering two points 
of damage in DNA can induce a deletion (Sollu, Pars et al.). However, some 
studies have shown that creating a lesion in the DNA double helix at a precise 
point and, simultaneously, providing exogenous DNA homologous to the target 
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site, the frequency of homologous recombination is far preferred over the non-
homologous end joining (Rouet, Smih et al. 1994). This mechanism can be used 
to introduce desired DNA modification (Lombardo, Cesana et al.). To introduce the 
DNA lesion in a site-specific manner it should be used enzymes to cut the DNA 
site and exact dates. These enzymes, known as artificial nuclease, are dimers in 
which each monomer is composed of a portion able to bind DNA in a specific site 
and of a portion ale to cut the binded  DNA. In particular, three are the most 
studied nuclease: the zinc finger nucleases (ZFNs), which have the cutting domain 
derived by FokI restriction enzyme and the DNA binding domain formed by 3-4 
modules 'zinc finger' each capable of recognizing a triplet of DNA; nucleases with 
structure 'TALE', instead, have cutting domain linked to DNA binding modules,  
where a  single module binds a single nucleotide and in general can also be 
present 18 modules in series; finally, we find the MEGA-nuclease having a very 
complex protein structure, in which the cutting domain is fused to the DNA binding 
domain. This property makes these nucleases inflexible and therefore not used to 
induce site-specific mutations for gene therapy. The nucleases most commonly 
used until today were the ZFNs. They are been numerous zinc finger modules able 
to recognize almost all the 64 possible nucleotide triplets allowing to have a lot of 
freedom in the choice of cutting site. To date, numerous studies have been 
conducted to limit the possible cutting errors in genomic regions. The cuts in the 
wrong regions, defined off-target, can cause deleterious effects in the target cell, 
such as gene inactivation, chromosomal translocations and oncogenes activation. 
To evaluate the more precise and safe artificial nucleases for use in gene therapy, 
many experiments have been carried out (Pattanayak, Ramirez et al.) and in vivo 
(Gabriel, Lombardo et al.) and there have been two very important elements: TALE 
nuclease are found to be much more specific in recognizing and cutting DNA than 
ZNFs and especially TALE were much less cytotoxic in vitro and in murine models 
(Mussolino, Morbitzer et al. 2011 (Tesson, Usal et al. 2011). 
Recently the nuclease TALE have been engineered to create the site-specific cuts 
in the β-globin gene near a site of pathological mutation. The correction of the 
damage was later stimulated by inserting therapeutic DNA as a template, and we 
obtained a β-globin locus correction in 20% of the cells. (Lin, Fine et al.). TALE 
technology has been applied to iPSC of thalassemia patients, with stunning 
results; the correction of the mutation occurred in a specific manner without 
produces cases of off-target (Wang, Ye et al. 2012). In addition to the correction of 
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the β-globin gene, several other research teams are paying special attention to  
gene therapy directed to the γ-globin gene. The use of synthetic zinc-finger 
transcriptional activators (ZF-TF) (Honors in 2013, Ji Q 2014) and transcriptional 
activator-like effector (TALE-TF) can be very interesting for binding the γ-globin 
gene promoter. Some in vitro studies using CD34+ cells have shown that the 
binding of these artificial nuclease at specific sites of the A γ-globin promoter 
produced an increase in γ-globin expression and HbF prodution (Wilber, Hargrove 
et al. (Graslund, Li et al. 2005) Costa, Fedosyuk et al.). The ZF-TF BCL11A was 
recently shown to function as a repressor of HbF expression (Roosjen 2014, Zhou 
2010, Sankaran 2008). As has been shown in previous chapters, the process of 
globin switch from HbF to HbA is very complex. An elaborate network of 
researchers studying molecular activators and repressors must cooperate for 
developing strategies by engineering these mechanisms (ZFN or TALE) in order to 
control the various elements of these network, it could be activate transcription 
and correction of the globin genes eliminating or reducing the genetic cause of this 
disease.  
h) MicroRNA and thalassemia 
MicroRNAs (miRNAs) are a class of small non-coding RNAs that can regulate 
gene expression binding in a sequence-specific manner the target mRNA. 
Depending on the degree of compatibility between miRNAs and mRNAs occurs 
silencing of mRNA and the complete its degradation. Studies on the possible 
application of these small molecules in the treatment of β-thalassemia have been 
underway since some years. In 2001 Sankar et al. brought the first evidence that 
the over expression of two miRNAs, miR-15a and miR-16-1 (act as repressors of 
Myb) were directly correlated with increased of HbF levels. Even the over 
expression of another microRNA, miR-486-3p binding BCL11A, is able to produce 
an increased of HbF. Likewise, inhibiting the expression of miR-486-3 it occurs an 
activation of BCL11A and down regulation of the γ-globin expression (Lulli, 
Romania et al.). Other microRNAs resulting upregulate in association with γ-globin 
gene expression are: miR-210 (Sarakul, Vattanaviboon et al.; Bianchi, Zuccato et 
al. 2009), miR-26b (Alijani, Alizadeh et al.) and miR-451(Kouhkan, Soleimani et 
al.). In contrast, miR-96 has been identified as an inhibitor of the mRNA of the 
gene array globin (Azzouzi 2011). In the context of β-thalassemia, to control the 
accumulation of α-chainscould be interesting use microRNAs to regulate the 
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mRNA α-chain content. Studies have shown that miR-144 negatively regulates the 
alpha globin (Fu, Du et al. 2009). 
Since all therapies so far described, innovative and not, we can see how the 
efforts of many researchers, in all examined areas, never stop to produce not only 
new therapeutic approaches, but also hope for all the patients affected by rare 
diseases. You can not define what is the safest and the most effective treatment, 
particularly the researchers have not yet reached at a summit of results, but 
certainly every day a lot of scientists are working to improve and optimize the 
treatments available to ensure to the patients a life style as much dignity as 
possible. 
 
5. Collection of biological samples in Biobank and Biobanks around 
the world 
In the last decades, researches have made very important goals in various 
medicine and pharmacology field. All knowledge, on the human genome and on 
the mechanisms involved in different diseases, have allowed to rebuild completely 
medical practices and to review classic treatment approaches. More and more 
frequently we talk about personalised medicine, which starts from specific 
characteristics of a patient in order to deliver the most appropriate therapy. 
Pharmacogenomics is a branch of personalised medicine which ideally allows 
each patient to have ‘tailor-made‘ treatments. However, until now, the use of 
pharmacology in clinical practice has rarely applied depending on many factors 
(Guttmacher and Collins 2003; Guttmacher, Porteous et al. 2007).  
In particular, it would be very useful to use electronic health records (EHR) 
systems that integrate genomic data of each patient on a large scale (Kohane 
2011). It would be possible to identify the best therapy for each patient by 
integrating all obtained data from an individual patient, and comparing them with 
the clinical information of other patients reported. There are several difficulties to 
create a truly personalized therapy (Bielinski, Olson et al.; Burke and Psaty 2007). 
Two major barriers are the availability of high quality samples with phenotype data 
and the validation in a timely manner of predictive genetic markers, in particular in 
the clinic context. The resolution of these problems could be represented by the 
establishment of a biobank (for example serum, tissues, DNA, RNA, cells) to have 
available biological samples of patients on which will be possible to carry out 
personalised clinical assay (Khleif, Doroshow et al.; Fiore and D'Avolio 2011). A 
51 
 
biobank is a systematic and organised collection of biological samples and all the 
information about the state of partecipant health (HEWITT 2011; RE 2011). In 
addition, it is essential to do genetic investigation doing DNA collection extracted 
from peripheral blood or buccal cells, for example. Detailed data regarding 
participants lifestyle (i.e. smoking, sporting etc.) can be very useful to evaluate all 
the influences and phenotype variations of the subjects (Kohane 2011). More 
informations are contained in the Biobank more scientists can evaluate how a 
small genetic variant could condition the phenotype. All informations and the 
biological samples contained in a biobank are strictly controlled by an Ethical 
Review Committee. All the people involved in the biobank data base necessarily 
have to sign an informed consent (McCarty CA 2005; Olson JE 2013). 
Although the first forms of biobank date back to the 70s, the real increase in 
development occurred at the beginning of the new millennium. In fact, the need to 
have a large number of patients for epidemiological studies concerning different 
diseases has led to pool a lot of samples collections relatively to different contexts 
(eg. Universities, hospitals, pharmaceutical companies) and countries around the 
world. 
There are different types of Biobanks now we describe some cases Biobank which 
are addressed to the study of specific variables and genetic disease-specific 
Biobanks (Riegman PH 2008; Terry SF 2011). In both cases, it would be very 
useful to monitor patients for a long period of time so as to could correlate the 
genetic variations to different prognostic factors. This can be very useful for 
prognostic patients stratification for the identification of therapeutic targets and for 
the best treatment choice. 
Others Biobanks can also be defined as 'general'. This type is much less common 
than the disease-specific Biobanks. In this case participants are not selected on 
the basis of a specific disease and risk factors, but they are recruited on the basis 
of different mechanisms, type of work, the place where they live for example (i.e. 
UK Biobank) (Ollier W 2005). These general Biobanks are very flexible and can 
support several studies in relation to investigate the correlation among genotype, 
phenotype, and geographical area, or they can represent  'reference standards' for 
other studies (Davey Smith G and PR. 2005). 
Independently of the typology, all Biobanks must respect very specific, and often 
restrictive, rules. 
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After signing the informed consent for a specific project, many participants decide 
to give consent to participate to future projects of which they do not know the 
details during recruitment. Different supervisory entities are involved to ensure the 
use of biological samples of participants for experimental purposes and always in 
compliance with the rules established by an ethical review committee. Also, ethics 
committees have to consider the researchers requests, protecting the participants 
privacy and establish the arrangements for treatment of all data derived from a 
clinical trial (O’Doherty KC 2011). 
From an institutional point of view a Biobank requires some specific entities. The 
institutional review board (IRB) is the essential government entity of a Biobank. 
However, in most cases are used formal committees to approve the use of both 
biological samples and data (McCarty CA 2011; Olson JE 2013). These 
committees known as community advisory boards (CABs) are composed of expert 
members in the scientific, ethical and clinical areas. CABs revise scientific 
protocols, control the number of samples in the Biobank and the assessment of 
the results in the different trials (McCarty CA 2011; Haga SB 2013). Additionally, 
they interface with the participants and manage disclosures in scientific, academic 
and industrial partners. Essentially CABs are at the centre of communication 
between the different Biobank levels (participants, researchers, funders, etc.). An 
other essential component of a biobank is the scientific aspect. 
CABs, as we said, control the scientific procedures, to standardize the 
experimental methods and evaluate the results obtained in laboratories. However, 
the results obtained must be validated in a Clinical Laboratory Improvement 
Amendments (CLIA), certified clinical laboratory. CLIA will validate all data 
obtained and will assess scientific methods to use (Wolf SM 2012). Only after 
verifying the experimental data, supervised by CLIA, it is possible to move forward 
to the scientific dissemination step controlled by CAB. 
About 80% of Biobanks are actually based on public universities or 
national/regional authorities and have been set for both population-based studies 
and for research purposes specific to the disease. Most collections are small or 
medium and mainly consist of DNA, serum and whole blood and/or cellular tissue 
samples stored at different conditions, and different types of data associated 
including medical, demographic, genetic and environmental informations (Global 
Directory of Biobanks 2015). Is important to note that most of Biobanks are 
individual collections (ie not forming part of a network or partnership) with 
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database systems, which, in many cases, are closed. They are still very few 
Biobanks that are implementing policies for sharing samples both within the EU 
and all around the world (Laage-Hellman, Hansson et al. 2001; Cambon-Thomsen 
2003). In this context, it is important to have a well-organized legislation regarding 
privacy and the needs of data protection between all the Biobanks involved. An 
important aim is to promote the network of Biobanks and maximize the benefits for 
public health, so at least a remarkable level of harmonization must be achieved. It 
would be appropriate to follow standard rules and scientific approaches (methods 
of sample collection, preservation, storage and data management). Experts have 
suggested the creation of a international (or at least European) organization 
network which establishes common operating procedures. 
Biological samples correctly stored and easily identified through barcodes provide 
to the entire scientific community the opportunity to make enormous advances in 
the study of various diseases. Furthermore, considering the large number of 
patients participating Biobanks give the real possibility to find new therapies 
significantly reducing the time required for clinical trials of new molecules.  
Existing Biobanks are very diversified and collect different types of samples: whole 
blood, plasma, serum, RBC(red blood cells), WBC (white blood cells), buffy coat, 
stem cells, bone and different cell lines. And yet buccal cells, DNA, RNA, proteins, 
different biological fluids such as urine, cerebrospinal fluid and amniotic fluid, solid 
tissues and samples from biopsies. In addition, these samples are collected from 
patients suffering from rare diseases or cancers such as basal cell carcinoma, 
bladder cancer, bone cancer, brain cancer, breast cancer, colorectal cancer, 
kidney cancer, ovarian cancer, pancreatic cancer, prostate cancer, lung cancer, 
melanoma, neuroblastoma, cancer liver and different types of leukemias and 
lymphomas. In addiction, several hospitals instituted with the aim of assisted 
fertilization provide a collection and storage service of embryos, oocyte and 
sperm. There are also Biobanks dedicated to patients with Alzheimer's, multiple 
sclerosis and other degenerative diseases. Should also mention the existence of 
Biobanks dedicated to plants and animals (Global Directory of Biobanks 
2015)(Appendix1). 
In the years this list is going to increase and we hope that Biobanks could help the 
researchers for developing new therapies and be able to improve the living 
conditions of the patients. 
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To date the scientific comunity has understood the importance of these structures 
so the member of Biobank are increasing considerably in a lot of country, because 
they have chosen to focus energies and funding for the development of new 
Biobanks.  
The Table 5 shows the amount of the principal Biobanks in the different countries. 
Unfortunately, you do not manage to have data sure 100% because the census of 
Biobanks in the world is complicated by the high variability of the samples 
collected in different parts of the world and by the lack of an official register. 
Moreover some Biobanks started initially as a little reality of research are 
subsequently developed as regular Biobanks. 
 
Table 5 Distribution of main biobanks spread around the world. 
Country Number of Biobanks 
Europe 126 
Canada 18 
USA 158 
Mexico 1 
Asia 25 
Australia 13 
Middle East 4 
 
The situation in Italy does not differ so much from the European and global 
condition. In fact in the absence of a national registry is not easy to know the 
number of Biobanks (small and large) operating in Italy. There are eleven 
Biobanks well established, but we must add to these some realities, which are 
gradually consolidating its existence. In May 2014 the document of the National 
Committee for Bioethics was published on the website of the Office of the Prime 
Ministers (www.governo.it/bioetica), in which was approved the opening of 
"Pediatric Biobanks". They will deal with of the collection of the biological children 
samples for the purpose of scientific research. At present there isn’t a register in 
which shows locations of pediatric Biobanks. 
As regards the thalassemias there are some Biobanks spread over several 
structures but which convey in a single entity, the Telethon Biobank (TNGB). 
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Within this  network the different Biobanks perform different tasks. Some of these 
are concerned with collecting and storing DNA in order to conduct genetic 
investigations; others collect cell samples such as T-lymphocytes, fibroblasts and 
lymphoblasts, but with regard to their use and storage detailed information are not 
suitable. Specimen collection is implemented by the gathering of patient 
informations. The services offered by the Biobanks are various and available on 
the website http://www.biobanknetwork.org.  
Other biobanks operating in thalassemia context might exist, but data and 
information are not reported, therefore it could be small companies not certified. 
It's difficult to find funds to invest in research, the regulatory fragmentation and the 
lack of coordination at the central level are slowing down development of the 
biobanks.  
If a European Biobank Networking Platform were successful in facilitating 
cooperation and creating a European biobanking logistics system, “then it would, 
de facto, create or increase the long term security of existing national biobanks 
and biobanking infrastructures (the distinction is between an investigative project 
and a pure logistics operation). Such long term security is essential if the full value 
to molecular epidemiology of population-based and case-based studies is to be 
realised. If the....concept is developed through cooperation between existing 
biobanks and biobanking infrastructures, then that cooperation will itself help to lay 
the basis for a successful union that also can engage successfully with others in 
the biomedical community and will strengthen (rather than detract from) those 
existing organizations” (Flyer 2006) 
 Now Biobanks can be considered a real cultural/scientific phenomenon of our 
decade. There are several areas involved, science, law, economics, and each 
must cooperate in order to allow the growth and the consolidation of these 
structures/organizations. Biobanks can provide a huge opportunity for 
development, research and knowledge and the beneficiaries will be all human 
beings and all future generations (An 2006).  
It is now clear the decisive role of Biobanks to accelerate scientific discoveries. To 
maximize results it is important to dedicate attention to the quality of numerous 
samples collected in the Biobanks, the creation of a partnerships network and 
financial infrastructures. For the future it would be desirable to create a single 
European/national Biobank having a centralized single coordination center and in 
which all the methods of collecting clinical data, specimen collection and storage 
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are standardized. Finally, to facilitate the circulation of specimens and scientific 
data obtained it would be appropriate to create a single model of informed consent 
adaptable to different types of studies. 
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Aim of the thesis 
 
The β-thalassemias are autosomal recessive genetic disorders caused by the 
absence or reduction of beta globin chains. Originally described in the 
Mediterranean area, to date β-thalassemias should be consisdered a worldwide 
pathology with more than 100,000 new cases annually with a high incidence 
especially in countries Africa and Central and Southeast Asia. The frequent and 
significant migration flows that have occurred over the decades have contributed 
irreversibly to the wide distribution of the disease. The β-thalassemia patients are 
treated with periodic blood transfusions associated to the assumption of iron 
chelating drugs and, when possible, with bone marrow transplantation (BMT). 
Despite scientific advances aimed looking for targeted and definitive treatments of 
the disease, to date a cure of β-thalassemia is not available. 
 
My PhD research activity has been conducted in the context of a multicenter 
project called THALAMOSS (THalassemia MOdular Stratification System) for the 
determination of a personalized therapy of β-thalassemia. This project, which has 
as coordinator Prof. Roberto Gambari of the Ferrara University, was developed 
with the approval of the ethics committees of Verona-Rovigo and Ferrara 
Hospitals. THALAMOSS is aimed at the development of a computerized system 
that enables β-thalassemia patient stratification according to clinical, genetic and 
molecular features in order to implement a personalized therapy 
In my study we have set the follows main steps: 
a) Genotype analysis of the base β-globin mutation all patients enrolled in the trial. 
b) Analysis of HbF-associate polymorphisms. 
c) Production of cellular 'biobank' consisting of CD34+ cells isolated from the 
peripheral blood from the β-thalassemia patients. This Biobank could offer many 
advantages for the patient, since multiple blood sampling are not further required 
and for research, since parallel comparison are possible. 
d) Design and performance in-vitro experiments aimed at identifying molecules 
that can stimulate HbF production, already been demonstrated to be a very 
effective therapeutic strategy. This is not a resolutive approach of the disease but 
greatly improves the clinical status of the thalassemia patient.  
e) Collection of information derived from all analyzes and experiments conducted 
in vitro to be combined with the clinical information for each patient. 
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This research acting will allow as a final goal patients stratification taking into 
account all the phenotypic/genotypic characteristics of the single individual and 
making it really possible the hypothesis of a personalized therapeutic approach. 
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Materials and Methods 
 
1. Biological samples collection 
 
For the biological samples collection has become necessary the approval of the 
Ethics Committee of Ferrara, project n°306201 approved on 20/06/2013 and the 
Ethics Committee of Verona-Rovigo district, project n°306201 approved on 
30/07/2014.  
The of peripheral blood samples collected from the patients from β thalassemia 
patients (before routine transfusion) and healthy subjects were obtained after 
informed consent with the collaboration of the 'Thalassemic Day Hospital' (DHT) of 
the Hospital and University Sant'Anna, Cona, Ferrara and of the DHT of Hospital 
Santa Maria of the Misericordia, Rovigo. Copy of each informed consent released 
to the patient at the time of blood sampling, in each of the two hospital structures is 
stored  
 
2. ErPCs Isolation and culture  
Peripheral blood (about 25 mL) were collect in Vacutainer LH treated tubes (BD 
Vacutainers, Becton Dickinson, UK) 
The 25 mL total blood received has been divided into three parts:1 mL necessary 
for the genomic DNA extraction, 100 uL required for the HPLC analysis and 
remaining were used in immediate to CD34+ cells isolation and purification.  
The PBMCs isolation were obtained from whole blood by Ficoll-Hypaque density 
gradient centrifugation (Lympholyte®-H Cell Separation Media, Cedarlane, 
Euroclone, Italy). Spin at 2000 rpm for 30 min, at RT, max acceleration without 
brake. After the separation of the various blood components, the ring was 
harvested and washed with 1X DPBS W/O CA-MG (GIBCO, Invitrogen, Life 
Technologies Carlsbad, CA, USA)  
At this point we have applied two different methods. 
Two-phase liquid culture (protocol A): the cellular pellet obtained by Ficoll Hypaque 
separation was resuspended in the medium containing α-minimal essential 
medium (α-MEM, Sigma-Genosys, Saint Louis, Missouri, USA), prepared from a 
powder and diluted with water; a solution of PEN-STREP (PEN-STREP 10000 
U/mL, Lonza, Verviers, Belgium); 10% FBS (Celbio, Milano, Italy); 10% 
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conditioned medium (CM), obtained from cell cultures of bladder cancer cells 
(5637); 1 ug/mL of cyclosporin A (Sigma-Aldrich), prepared from cyclosporine 
absolute ethanol and diluted in 1X DPBS (GIBCO), in the ratio 1:1. After 7 days in 
phase I culture, the nonadherent cells were washed once with 1XDPBS (GIBCO), 
and then cultured in phase II medium. This medium contains: 𝛼-MEM (Sigma 
Genosys), 30% FBS (Celbio), 1% deionized bovine serum albumin (BSA, Sigma 
Genosys), 10−5M 𝛽-mercaptoethanol (Sigma Genosys), 2mM L-glutamine (Sigma 
Genosys), 10−6M dexamethasone (Sigma Genosys), and 1 U/mL human 
recombinant erythropoietin (EPO Tebu-bio, Magenta, Milano, Italy), and stem cell 
factor (SCF, BioSource International, Camarillo, CA, USA) at the final 
concentration of 10 ng/mL.  
Biobank protocol for lhe CD34+ isolation and purification (Protocol C): cells 
Isolation of hematopoietic progenitor cells by CD34+ MicroBead Kit using LS 
MiniMACS column placed in the magnetic field of the autoMACS Separator (both 
from Miltenyi Biotec, Bergisch Gladbach, Germany) according to manifacture’s 
protocol. All steps from this moment onwards must be conducted strictly in ice. 
Briefly: Add 100 uL of CD34+ MicroBead at the cells PBMCs obtained from 
separation by concentration gradient. The cellular pellet was resuspended in 600 
uL of PBS 1% BSA (bovine serum albumin) solution. Subsequently were added 
100 uL of CD34+ microbeads. The tube containing the cell suspension and the 
microbeads should be kept in the dark and incubate with gentle agitation at 120 
rpm for 15 min at 4°C. It’s necessary equilibrate the columns for MACS separation 
before use. Work in sterile conditions in biohazard cabine, where you will use the 
unit magnet autoMACS. Apply 500 ul of CD34+ MicroBead binded cells onto the 
column until exhaustion of the sample by alternating of washing with Beading 
Buffer 
To increase the purity of CD34+ cells, the eluted fraction can be enriched over a 
second LS Column. Repeat the magnetic separation procedure as described by 
using a new column (Wang, Hsu et al. 2001). Centrifuge the cells at 1200 rpm, at 
room temperature for 5 min, remove the supernatant and resuspend the cells in 5 
mL of growth medium and transfer in a T25 flask. 
The CD34+ cells were maintained in an expansion medium containing: 5 mL of 
medium StemSpan Serum-Free Medium Expansion (VODEN, Vancouver, 
Canada); 50 microliters StemSpan® CC100 Cytokine Cocktail for Expansion of 
Human Hematopoietic Cells Stem Cell Technologies (VODEN); erythropoietin 
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(EPO, Tebu-bio) 2U/mL final concentration; dexamethasone (Dexamethasone 21-
phosphate disodium salt, Sigma-Aldrich) 10-6 M final concentration, 50 microliters 
PEN-STREP (Lonza). During the expansion phase, the cells were diluted to 
maintain an ideal concentration of 1x106cells/mL. 
 
3. Freezing 
Achieved the maximum expansion, the CD34+ cells were frozen following the 
Naldini method’s: IMDM (Iscove's modified Dulbecco's Medium, Life Tecnologies) 
with 50% FBS (Celbio, Milan, Italy) and 10% DMSO (Dimethyl Sulfoxide RPE-
ACS, Carlo Erba, Italy). The cells in freezing medium preferably about 5x106 cells 
in 1mL) were immediately placed at -80°C and subsequently stored in liquid 
nitrogen (-147°) 
 
4. Thawing 
The cells were thawed in 5 mL of IMDM (Life Tecnologies) 10x 5% FBS medium 
and incubated at 37°C with controlled humidity with 5% CO₂ in expansion medium 
in according to the protocol C. 
 
5. Benzidine staining 
The benzidine assay allows to evaluate erythroid differentiation. 5uL of 0.1mM 
benzidine, resuspended in 2.86 % glacial acetic acid and activated with 33% 
H₂O₂, were added to the same volume of the cells. The percentage of resulting 
blue cells indicates the level of erythroid differentiation. 
 
6. Treatment with HbF inducers. 
About four days after thawing the CD34+cells have been treated with HbF inducers 
using a concentration previously tested on erythro-leukemic K562 cells. We used 
2/3x106 cells for RNA extraction to T0. We have tested the cells with different types 
of HbF inducers: Mithramycin (Sigma-Aldrich), Hydroxyurea (Sigma-Aldrich), 
Rapamycin (Calbiochem, Merk Millipore, San Diego, CA, USA), Resveratrol 
(Sigma-Aldrich). At the end of the treatment we have performed another benzidine 
assayto test erythroid differentiation after treatment. Then the cells were washed 
twice with1X DPS (GIBCO). From the pellet obtained we have done haemoglobin 
analysis by HPLC and transcript analysis by RNA extractionand RT-qPCR 
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7. RNA extraction 
All reagents and materials used were RNase–free. The cells (5-10x106) were 
centrifuged at 1,200 rpm for 5 minutes at 4°C, from the pellet obtained the total 
cellular RNA was extracted by TRI Reagent® (Sigma-Aldrich). After incubating for 
3 minutes at room temperature, 200 uL of chloroform were added, stirring well, 
and incubating on ice for 5 minutes. The samples were then centrifuged at 12,000 
rpm for 10 minutes at 4°C. To the collected aqueous phase an equal volume of 
isopropanol was added. The samples were then placed at -80°C for at least 1 
hour. The RNA precipitate was centrifuged at 12,000 rpm for 20 minutes at 4°C, 
washed with 500uL of cold 70% ethanol, re-centrifuged, freeze-dried and 
resuspended in 20uL of water RNase–free. The extracted RNA was analyzed by 
electrophoresis on 0.8% agarose gel. 
 
8. Synthetic oligonucleotides 
The oligonucleotides used as primers in the chain polimerization and sequencing 
reactions were synthesized by Sigma-Genosys (Cambridge, UK) (Table 6), while 
those used for the Real Time quantitative PCR were purchased from Applied 
Biosystems (Applera Italia, Monza, Italy). All the oligonucleotides were designed 
using the software Primer ExpressTM, version 2.2 (Perkin-Elmer Applied 
Biosystems) and the sequences are reported on Table 7. 
 
 9. RT-PCR and RT qPCR analysis 
For gene expression analysis 1 μg of total RNA was reverse transcribed by using 
the TaqMan® Reverse Transcription Reagents and random hexamers (both 
Applera Italia, Applied Biosystems, Life Tecnolgies). 
Quantitative real-time PCR assay, to quantify the expression of the globin genes, 
was carried out using using gene-specific double-quenched probes. Probes are 
labeled in 5’ with different fluorochromes, whereas in 3’ the BHQ (Black Hole 
Quencher™) is present.Reaction mixture contained 1X iQTM Multiplex Powermix 
(Bio-Rad, Hercules, California, USA), 300 nM forward and reverse primers and the 
200 nM probe. The assays were carried out in iCycler IQ5 (Bio-Rad). After an 
initial denaturation at 95°C for 30 sec, the reactions were performed for 50 cycles 
(95°C for 10 s, 60°C for 45 s). To compare gene expression of each template 
amplified was used ΔΔCt method employing software IQ5 (Bio-Rad).  
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Table 6 Primers used in the polymerase chain reactions and in the sequencing reactions. 
For each primer the nucleotide sequence, Melting temperature (Tm) and the orientation of the 
primer have been reported. 
Primer Sequence (5’-3’) Tm (°C) Orientation Use 
BGF 5’-GTGCCAGAAGAGCCAAGGACAGG-3’ 72,1 forward 
PCR and 
sequencing 
reactions. 
T12F 5’-AGACCTCACCCTGTGGAGCC-3’ 67,9 forward 
 sequencing 
reaction 
T3F 5’-ACAATCCAGCTACCATTCTGCTTT-3’ 65,7 forward 
PCR and 
sequencing 
reactions. 
BG6F 5’-CGCTTTCTTGCTGTCCAATTTC-3’ 66,7 forward 
sequencing 
reaction 
BG5SF 5’-GCCTGGCTCACCTGGACA-3’ 66,7 forward 
PCR and 
sequencing 
reactions. 
BG4 5’-TCAGGAGTGGACAGATCCCC-3’ 66,5 reverse 
sequencing 
reaction   
T12R 5’-AGTTCTCAGGATCCACGTGCA-3’ 67,1 reverse 
PCR and 
sequencing 
reactions. 
BGR 5’-CACTGACCTCCCACATTCCCTTTT-3’ 69,8 reverse 
PCR and 
sequencing 
reactions. 
BGi2R 5-‘GTTGCCCAGGAGCTGTGG-3’ 67,1 reverse 
PCR and 
sequencing 
reactions. 
 
Table 7 Primers and probes employed in the multiplex quantitative real-time PCR. The 5’ and 
3’ chromogenic molecules are also reported in the sequence. 
Primer Sequence (5’-3’) 
forward primer α-globin 5’-CGACAAGACCAACGTCAAGG-3’ 
reverse primer α-globin 5’-GGTCTTGGTGGTGGGGAAG-3’ 
α-globin probe 5’-HEX-ACATCCTCTCCAGGGCCTCCG-BHQ-3’ 
forward primer β-globin 5’-GGGCACCTTTGCCACAC-3’ 
reverse primer β-globin 5’-GGTGAATTCTTTGCCAAAGTGAT-3’ 
β-globin probe 5’-Texas Red-ACGTTGCCCAGGAGCCTGAAG-BHQ-3’ 
forward primer γ-globin 5’-TGACAAGCTGCATGTGGATC-3’ 
 reverse primer γ-globin 5’-TTCTTTGCCGAAATGGATTGC-3’ 
 γ-globin probe 5’-FAM-TCACCAGCACATTTCCCAGGAGC-BHQ-3’ 
forward primer RPL13A 5’-GGCAATTTCTACAGAAACAAGTTG-3’ 
reverse primer RPL13A 5’-GTTTTGTGGGGCAGCATACC-3’ 
RPL13A probe 5’-CY5-CGCACGGTCCGCCAGAAGAT-BHQ-3’ 
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10. High Performance Liquid Chromatography (HPLC) 
The cells pelleted and washed once with PBS1X after the treatment (Gibco, 
Invitrogen, Life Technologies) were lysed in water with cycles of freezing-thawing 
in dry ice. Hb proteins present in the lysates were separated by cation-exchange 
HPLC, utilizing a Beckman Coulter instrument System Gold 126 Solvent Module-
166 Detector. Hemoglobins were separated using a Poly CAT-A column, samples 
were eluted in a solvent gradient utilizing aqueous sodium chloride–BisTris–KCN 
buffers and detection was performed at 415 nm. The standard controls were the 
purified HbA (Sigma-Aldrich) and HbF (Alpha Wassermann, Milano, Italy). 
 
11. Genomic DNA Extraction 
The DNA was extracted from 200-300 mL of whole blood using QiAmp DNA Mini 
Kit & QiAmp DNA Blood Mini Kit (QIAGEN, Hilden, Germany) according to 
manifacture’s protocol. Two DNA elutions were carried out, each with 50uL of AE 
buffer followed each by a incubation of 5 minutes at room temperature to increase 
the yield of DNA and centrifugation for 1 minute at 8,000 rpm always at room 
temperature. The DNA obtained was stored at -20 ° C  
 
12. Agarose gel electrophoresis 
The genomic DNA extracts were analyzed by electrophoresis on agarose gel 
0.8%. The agarose powder was dissolved in 100 mL of 1X TAE buffer (0.04 M Tris-
Acetato, 0.001 M EDTA pH 8), boiling until the agarose melt completely. The 
solution were cooled and 0.5 μg/mL ethidium bromide was added. The gel was 
done solidify for about 30 minutes in a clean casting plate with an appropriate 
comb and then immersed into 1X TAE buffer. 1 uL of loading buffer (0.25% Orange 
G, 50% glycerol in TE) was added to each sample before being loaded. On both 
the sides of the gel a molecular weight marker was added. 1 uL of 1kb DNA 
Ladder (10,000, 8,000, 6,000, 5,000, 4,000, 3,500, 3,000, 2,500, 2,000, 1,500, 
1,000, 750, 500, 250 bp) (MBI Fermentas) or pUC Mix Marker 8 (1,116, 883, 692, 
501, 489, 404, 331, 242, 190, 147, 111, 110, 67 bp) (MBI Fermentas) was up to 
the loading volume with water. The electrophoresis was performed at 80 Volt. The 
DNA was visualised using UV rays and then photographed with a Polaroid 
camera.  
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13. Quantification of DNA spectrophotometer 
The spectrophotometric quantification was performed using the spectrophotometer 
SmartSpecTM Plus (BIORAD, Hercules, California, USA). Each quantification 
required from 0.5 to 1 uL of genomic DNA, in order to determine an optical density 
at 260 nm (OD260 nm) of 0.1 to 1.0: after deducting the value of optical density of 
the blank, the concentration of the extracted DNA was calculated considering that 
1 OD260 nm corresponds to the concentration of 50 ng/uL. For each sample was 
also measured the optical density at 280 nm to determine the possible 
contamination of protein molecules, taking into account that the ratio 
OD260nm/OD280nm of the pure DNA is between 1.8 and 2.0. 
 
14. Polymerase Chain Reaction (PCR) 
The polymerization reaction chain is used to amplify a specific genomic sequence, 
in our case a specific region of the β globin gene. Each reaction was carried out in 
a final volume of 100 uL, in the presence of 300 ng of genomic DNA, 1X buffer (10 
mM Tris-HCl pH 8.8, 1.5 mM MgCl2, 50 mM KCl, 0.1% Triton X-100), 33uM 
dNTPs, 2U/uL of DyNAzymeTMII DNA Polymerase (Finnzymes, Espoo, Finland), 
0.25uM forward and reverse primers and ultra-pure water. Each reaction was 
subjected to an initial denaturation step at 96°C 3 minutes, followed by a second 
phase of 35 thermal cycles of amplification, each consisting of three steps: 30 
seconds at 95°C for denaturation of DNA, 20 seconds at 65°C for the pairing with 
the filaments denaturing of the template DNA (the temperature varies according to 
the Melting Temperature of the primers used), 1 minute at 72°C for the elongation 
of DNA strands on the copied mold on the part of 'enzyme. The third and final 
stage consists of 10 minutes at 72°C to complete the process of elongation of all 
the filaments obtained. 
 
15. Purification of PCR products with MicroCLEAN (Microzone Limited) 
PCR products purification was carried out to remove the unincorporated PCR 
primers before sequencing. An equal volume of MicroCLEAN (Microzone Limited) 
reagent was added to each PCR product, then, after carefully mixing and 
incubating for 5 minutes at room temperature to allow DNA precipitation, this was 
collected by a first centrifugation at 13000xg for 10 minutes and then a second one 
for 1 minute to be able to remove all the supernatant. Finally, the desired volume 
of ultrapure water was added, before incubating at room temperature for 10 
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minutes and then mixing to allow the complete DNA dissolution. The purified 
samples were stored at -20°C until sequencing. 
 
16. Sequencing Reaction: "Sanger"method 
The reaction sequencing allows us to analyze the nucleotide sequence of the DNA 
and then to be able to evaluate the presence of β-globin gene mutation. 
The PCR products purified obtained were sequenced according to Sanger’s 
method (Sanger et al. 1977) with primers reported in Table6 order to identify a 
possible pathogenic mutation. Sequence reactions were performed in a final 
volume of 20 uL, containing 60 ng of PCR template, 3.2 pmol of sequencing 
primer and ultrapure water to a 12uL volume. Then 8 uL of Terminator Ready 
Reaction Mix of ABI PRISM® BigDye™ Terminator Cycle Sequencing Ready 
Reaction Kit (Life Technologies), was added, containing the four differently-labeled 
dideoxyribonucleotides (ddNTPs), the AmpliTaq® DNA polimerase, MgCl2 and 
Tris-HCl buffer at pH 9.0. A total of 45 amplification cycles were performed, as 
follows: denaturation, 96°C, 10s; annealing, 65°C, 5s; elongation, 65°C, 3min. 
The reaction products were then purified from unincorporated ddNTPs by using a 
96-well MultiScreen™ (Millipore Corporation) plate: after loading on pre-hydrated 
wells filled with Sephadex™ G-50 Superfine (Amersham Biosciences), samples 
were recovered by centrifugation at 900xg for 6 minutes and dried under vacuum. 
Sequencing was finally performed by BMR Genomics (Padua), while the obtained 
sequence data were analyzed by the Sequence Scanner, version 1.0 (Applied 
Biosystems), software. 
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Results 
 
The cellular Biobank is a collection of cryopreserved erythroid progenitor cells 
isolated from β-thalassemia patients. These patients can be stratified on the basis 
of molecular, genetic and clinical informations. The patients stratification offers the 
possibility of implementing a new therapeutic approach in which, on the basis of 
the specific characteristics of each one, we develop the formulation of 'ad 
personam' treatment. 
 
1. Sample collection 
All the subjects, who have contributed to the establishment of the cellular Biobank, 
gave their positive consent in total freedom and without any remuneration. The 
collection of the biological samples was necessary approved by the Ethics 
Committee of Ferrara, project n°306201 on 20/06/2013 and by the Ethics 
Committee of Verona-Rovigo district, project n°306201 on 30/07/2014.  
The blood sampling were done before the routine blood transfusion of the β-
thalassemia patients and healthy subjects, in collaboration with the 'Thalassemic 
Day Hospital' (DHT) of the Hospital and University Sant'Anna, Cona, Ferrara and 
of the DHT of Hospital Santa Maria della Misericordia, Rovigo. Copy of each 
informed consent released to the patient at the time of blood sampling, in each of 
the two hospital structures was stored.  
The cellular Biobank that we set up to date is composed of 75 subjects 
(Appendix2). Most of them are β-thalassemia patients and only a small fraction 
(10 subjects) is composed of healthy subjects. The participants recruited by these 
two health center come from different areas of the Veneto, from the Ferrara 
Province and in sporadic cases from non-EU areas (individuals immigrants). The 
average age of the subjects is about 40 years with a fairly heterogeneous 
distribution ranging from 14 years to 65 years. Approximately 54.2% of the 
participants are women. 
As it is clearly apparent from the graph in Figure 6 the genotypes mainly present 
are those most common in the geographic areas of the individuals. In particular, 
the genotype β039/β039, β+IVSI-110/β039 and β+IVSI-110/β+IVSI-110 are present 
with a percentage of 30, 22% and 11% respectively. On the contrary, other 
genotypes are poorly represented, demonstrating the high distribution of β039 and 
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β+IVSI-110 mutations in the Emilia Romagna and Veneto areas from which the 
subjects are originating. 
At the moment of the blood sample collection necessary for the isolation, 
expansion and the following freezing of CD34+ cells, for the implantation of the 
Biobank, two other small volumes of blood are stored in parallel that will be used 
for DNA  extraction and HPLC analysis conducted directly by lysing the blood 
sample. 
 
Figure 6 Genotype distribution. A) Here it’s reported a table containing the genotype, the subject 
number having the specific indicated genotype and the vial number respectively stored in the 
Biobank. B) It’s graphicated the pie chart reproducing the distribution (expressed as percentage) of 
the patient genotype represented in the cellular Biobank.   
 
Regarding the genotyping of each patient, our laboratory at the Ferrara University 
was full responsible for sequencing all the β-globin gene (Figure7), while the 
analysis of some HbF related polymorphisms were carried out at the Regional 
Hospital for Microcythemia in Cagliari. 
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Figure 7 Primers used for genotye characterization of β-globin gene of the patients involved 
in the Biobank production. A schematic representation of the primers located in the β-globin gene 
and used in PCR and sequencing reactions. Primers of the same color can be used in pairs.   
 
 In particular polymorphisms rs1427407 (G/T), rs10189857 (A/G) were 
investigated for BCL11A. Also the XmnI polymorphism rs74482144 (+/-) in position 
-158 G-γ promoter and polymorphism HBS1L-Myb rs9399137 (T/C) located on 
chromosome 6q23.3 were analysed (Figure8). 
 
 
Figure 8 Polymorphisms associated with high HbF levels. The graphs shows incidence 
percentage for each polymorphism investigated in the β-thalassemia patients involved in the 
cellular Biobank. The homozygous phenotype not associated with high HbF levels (red), 
heterozygous (yellow), and homozygous phenotype associated with high HbF levels (black) are 
shown. 
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In particular about BCL11A rs1427407 (G/T), the 28% of the Biobank patients 
adherents are HbF related polymorphism carriers and only 1% have an 
homozygosity "T/T" condition. The rs10189857 polymorphism, instead, is present 
in 65% with 7% homozygous in the investigated patients. So rs10189857 (A/G) is 
BCL11A polymorphism more prevalent among the patients who joined the Biobank 
production. The HBS1L-Myb rs9399137 (T/C) polymorphism was found in 47% of 
cases analyzed with a 3% of C/C homozygous patients Finally, 17% of patients 
collected in Biobank are carrier of the XmnI rs74482144 (+/-) polymorphism and 
only 1% is homozygous T/T; thus this polymorphism is less frequent in the 
geographical area where the Biobank samples are representative. 
 
2. CD34+ cells: isolation, expansion and freezing 
Each person who participated in the project was expected to donate about 20-25 
ml of peripheral blood. At this point, we applied two complementary techniques in 
succession to obtain a selection of CD34+ cells.  
-Ficoll Hipaque. This phase allows to separate the different components of whole 
blood according to the density gradient. In particular, we isolated lymphocytes, 
macrophages, fibroblasts and erythroid precursor cells from the remaining cellular 
blood components. 
-MACS Method (Magnetic Assay Cell Sorting): this method uses magnetic 
microbeads having a surface structure that can recognize and selectively bind 
CD34+ cells. This step allows to set up very pure cell culture.  
For the development of the expansion medium for optimal growth of CD34+ cells a 
protocol described for the first time by Leberbauer was employed. This medium 
was later modified by Breda and Rivella, who have employed it in studies for β-
thalassemia treatment with the gene therapy method. This medium contains 
StemSpan Serum-Free Medium Expansion, StemSpan® CC100 Cytokine Cocktail 
for expansion of human hematopoietic cells stem cell, erythropoietin (EPO), 
dexamethasone 21-phosphate disodium salt and PEN-STREP.  
We have firstly evaluated the ability of this medium to stimulate the cell growth 
without influencing their natural differentiation state; then we decided to use it 
during CD34+ cells expansion phase and after thawing.(Figure9) 
The number of cryovials that can be obtained for each subject with this method 
starting from a simple peripheral blood collection was found to be very variable. 
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We have noticed that in the various stages of the Biobank setting up some 
parameters considerably influenced the successful of the cellular expansion.  
 
 
Figure 9 Purification and production of the cell collections. 20-25 mL of blood from each subject 
are used to purify the CD34
+
 cells by ficoll and MACS separation. Than, the cells are amplified in 
expansion medium. Finally, the cells are frozen and stored in the Biobank when they reach the 
maximum progenitor cell expansion. Also, with a little amount of material we make sequencing 
reaction and HPLC analysis.  
 
The clinical condition of the patient and the time that elapses from blood 
withdrawal until the start of the blood processing are two very important factors. 
We also have noticed that it is very difficult to determine the timing and 
standardize the experimental approach in order to obtain same responses from all 
samples employed. The cells of each patient, in fact, grow following its own 
timeline. The ability and experience of the operator are essential to understand 
what will be the trend of the culture and stimulate the growth of cells at the time 
and in an appropriate way. 
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Overall we can say that after the purification step from the blood we obtain only a 
few hundred of CD34+ cells. To maintain a good level of vitality and to stimulate 
their growth we have noticed that it is appropriate to maintain a concentration of 
the culture of about 1x106 cells/mL. When the culture has reached the peak of its 
growth potential, that is, after about 11 days, the cells are ready to be stored in the 
cellular Biobank. Each cellular cryopreserved aliquot will be formed by about 5x106 
cells. This is the optimal minimum number of cells to ensure a good recovery of 
the cryopreserved cultures after thawing. 
 
3. Kinetics of EPO-induced erythroid differentiation following 
subculturing of cryopreserved ErPCs from β-thalassemia patients.  
In order to assess what impact could have the freezing step on our cellular 
cultures we have thawed cells from 36 of the 75 subjects included in the cellular 
Biobank. We have performed on cultures isolated selected subjects with four 
different genotypes (β+=16 subjects, β0=6 subjects, β+/β0=12 subjects and 
HbS/β0=2 subjects) in order to verify the behavior of the cells having different 
thalassemia mutations. 
The degree of erythroid differentiation was evaluated by a benzidine assay 4 days 
and 9 days after thawing; the percentage of resulting blue cells indicates the level 
of erythroid differentiation within the cellular population. We have selected four 
thalassemia genotypes in order to obtain a more heterogeneous samples present 
in cellular Biobank. As we can see in Figure 10, in all cellular cultures analyzed, 
the 4th to 9th day after thawing, an increase of the percentage of B+, 
demonstrating the ability of the cells to resume their viability after freezing, was 
observed. 
The data obtained allowed us to conclude that the shock of thawing step 
performed on cryopreserved samples does not affect the natural differentiation 
process.  The cell viability and the resumption of the differentiation process are two 
key elements to determine how the cells of the can be useful and reliable to 
conduct experiments on hemoglobin induction after storage in liquid nitrogen. 
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Figure 10 Erythroid differentiation of ErPcs from patients with different genotype during the 
culture. In the graph are reported the mean ± SD (as percentage) of B
+
 obtained by benzidine 
assay at 4
th
 day (orange) and 9
th
 day (blue) of culture. For each genotype is specified the number 
of patient analyzed. 
 
To go deeper into this aspect, we have selected 10 patients and we have 
compared the B+ value obtained by the benzidine assay in three different stages of 
the culture: before freezing and 4 days and 9 days after thawing. 
As shown in Figure 11 a progressive increase of erythroid differentiation in 
function of time was recorded in all 10 patients in a very clear manner. 
 
Figure 11 Erythroid differentiation evaluated at different days of cell culture. The graph 
shows with different colors the %B
+
 value from 10 patients at three time of cell culture: before 
freezing, 4t
h
 and 9
th
 day from thawing cells (*=P<0,05). 
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The confirmation of a good cell viability after thawing in all samples analyzed is 
critical to the validation of the cellular Biobank. 
A further confirmation of the cell samples stability stored in the biobank is 
represented in Figure 12. We have reported an example of chromatograms 
obtained by an HPLC analysis concerning three cell samples derived from β-
thalassemia patients with different genotypes. The hemoglobins, represented in 
the form of easily discriminable peaks, are recognizable because each elutes by 
the HPLC column at a specific 'retention time'. 
 
 
Figure 12 HPLC analysis of ErPCs obtained at three time of the cell culture. The 
chromatograms represent the hemoglobin profile obtained at three time of cell culture: before 
freezing, 4t
h
 and 9
th
 day from thawing cells. The chromatograms of three patients affected by β-
thalassemia (Fe6, Fe57, Fe37) presenting different genotypes are reported as example.  
 
For each patient different chromatograms, corresponding to three different 
moments of the cultures, are reported. We can see that hemoglobins retain a 
similar trend in the various moments of the culture, comparing the chromatograms 
of each patient. 
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4. Validation of cell samples stored in the Biobank 
The experiments conducted to date have shown that CD34+ cells isolated and 
cultured with this new protocol and then cryopreserved in liquid nitrogen are still 
able to undergo a natural differentiation process. We also investigated how the 
genotypic characterization associated with analysis of specific polymorphisms  
would be useful in assessing the differentiation of cells of each patient in a more 
predictive manner. 
 
4.1. Biobanked samples of a same β-thalassemia patient frozen and 
subcultured at different time maintain the same hemoglobin pattern. 
To assess how the cellular samples collected and stored in the Biobank can really 
be used to conduct several experiments in an indeterminate period of time, we 
have investigated whether cells cryopreserved for increasing length of time 
maintain the same pattern of hemoglobin production. For this purpose, two cellular 
aliquots belonging to the same patient and derived from the same blood collection 
were thawed after several months one from the other and the hemoglobin pattern 
was evaluated by HPLC analysis. A representative example of the HPLC 
chromatogram is shown in Figure 13. As we can see the trend of hemoglobin is 
nearly perfectly superimposed showing that cryopreservation does not alter the 
hemoglobin gene expression of the cells stored in Biobank.  
 
Figure 13 Erythroid independent cultures of the same blood collection from a patient. HPLC 
analysis (chromatograms in A and B) are carried out on the thawed cells purchased by two different 
vials and obtained from the same blood collection. Each hemoglobin peak is eluted from the 
column with a defined 'retention time'. 
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4.2. Biobanked samples originated from different blood sampling of a 
same β-thalassemia patient maintain the same hemoglobin pattern.  
A furher validation of the cellular Biobank was performed on several withdrawals 
done at different time points on a same patient. The aim of this experiment was to 
verify whether the hemoglobin pattern is reproducibly obtained starting from 
different withdrawals of a same patient. To investigate this issue, we selected three 
patients, AVLTF, AVLTA and AVLTQ, exhibiting three different mutations of the β-
globin genes (β039/β039, β+IVSI-6/β039, β+IVSI-6/β039 respectively) and/or 
different endogenous levels of HbF. Cryopreserved cells originated from two 
different withdrawals were subcultured and the hemoglobin pattern analyzed by 
HPLC. The results presented in Figure14 are expressed as a percentage of each 
hemoglobin peak obained following quantitative evaluation of the HPLC 
chromatograms. Interestingly, the result obtained demonstrated that the trend of 
hemoglobin was found to be the same in cryopreserved cells originating from 
different withdrawals. 
 
 
Figure 14 Erythroid cultures of blood collection from different patients. The panels 
correspond to three different patients (A) AVLTF, (B) AVLTA and (C) AVLTQ. The histograms 
indicate the mean of hemoglobins expressed as percentage. The HPLC analyzes in each panel 
were carried out on two cell cultures obtained from independent blood collection of the same 
patient. 
 
4.3. Biobanked samples thawed and subcultured in different 
laboratories exhibit a similar pattern of hemoglobin production. 
 One of the most interesting applications of the developed cellular Biobank is 
based on the possibility of sending multiple cellular aliquots of the same patient in 
different laboratories of the world in order to conduct independent experiments 
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depending from the expertise of each laboratory involved. One possible use of this 
network-based project is the independent validation of novel HbF inducers. The 
confirmation of the HbF inducing capability by independent research group is of 
course very important to transfer basic/applied observations to pre-clinical and 
clinical appplications. A prerequisite of thios approach is the maintenance of the 
phenotype. To verify this issue, we performed experiments in parallel with Dr. 
Rivella at the Weil Medical College of Cornell University in New York. Aliquots of 
cells from different patients isolated and frozen at the Ferrara University have been 
sent to New York. The cell samples were thawed in parallel at Ferrara University 
and at Cornell University, the cells were allowed to differentiate using exactly the 
same culture protocol and the pattern of hemoglobin production analysed by 
HPLC using same experimental conditions. As we can see in the representative 
example given in Figure 15 (panels A and B), the data obtained in the two 
laboratories were very similar. 
 
 
Figure 15 HPLC analyses performed on the ErPCs obtained from the same blood collection, 
but from cultures made in different laboratories. In the figure are reported the chromatograms 
of cellular lysates derivated from culrures performed in A, Ferrara’s University and B, New York’s 
University. Each hemoglobin peak is eluted from the column with a defined 'retention time'. 
 
The experiment was conducted in parallel on the cellular samples derived from 12 
patients of the Biobank each identified with a colored dot (Figure16).  
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The trend line defined by the correlation of induction in the two laboratories is R2= 
0.91 for HbF and R2= 0.94 for HbA. in both experiments. These values indicate 
that HbF and HbA levels are, in all 12 patients, very similar when the analysis is 
conducted at Ferrara University and at Cornell University.  
 
 
Figure 16 Comparison of HPLC analyses performed on the 12 different ErPCs obtained from 
the same blood collection, but from cultures made in different laboratories. The comparison 
regard the analyses made respectively at Ferrara’s University and New York’s University. The two 
panels show the correlation of percentage values of HbF (A) and HbA0 (B) on 12 patients picted 
using different colors. 
 
 
4.4. Conclusions. All experiments conducted have validated the stability of the 
cells stored in the Biobank and confirmed the experimental repeatability and 
reliability of our cellular samples. Each of these points is crucial for the creation of 
a Biobank. The possibility of transferring the stored samples in the Biobank, 
according to the international Biobank laws, contributes to the formation of 
networks essential for progress in which several laboratories collaborate with each 
other to identify the best therapies and to progress in scientific research.  
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5. Induction of Biobanked CD34+ cells versus two liquid phases Fibach 
protocol. 
After the initial validation of the Biobank allowing to conclude that the phenotype of 
the β-thalassemic cryopreserved cells is maintained, we were interested to verify 
whether the results obtained using crypreserved biobanked samples are in 
agreement with those obtained with the two liquid phase procedure originally 
developed by Fibach (Fibach, Manor et al. 1989). For this comparison, the 
response of cells after treatment with an HbF inducer was analyzed. The Fibach 
protocol is a method widely validated and appreciated by the entire scientific 
community and also used in several laboratories to verify the effects of HbF 
inducers.  
We selected five patients with different genotypes representative for the patients 
recruited for the development of the Biobank. The cells of each patient were 
maintained in culture in parallel following the procedures and times provided in the 
Fibach protocol and those used for the preparation of the cellular Biobank. The two 
parallel cell cultures were treated with mithramycin (MTH) at the same 
concentration. For both methods, the hemoglobin production was evaluated by 
HPLC analysis and the results considering the HbF production and the level of the 
α-globin peak comparatively analyzed. It should be underline that usually the 
increase of HbF corresponds to a reduction of the α-globin peak. In Figure17 all 
the data reported as treated/untreated ratios expressed in percentage. As it is 
evident, all the cellular cultures that have followed the protocol of expansion used 
for the generation of the Biobank exhibit basal HbF levels higher than those 
exhibited by the cells cultured with the Fibach method. However, in all the cellular 
cultures it was possible to appreciate an increase in the level of HbF hemoglobin 
correlated with a reduction of the α-globin peak. This experiment allowed us to 
demonstrate that the cells stored in the Biobank are sensitive to treatment with 
HbF inducers albeit starting from higher levels of HbF high levels. Furthermore, we 
observed a similar trend in the cell cultures when the two methods are considered. 
This results is crucial for our research interests because it demonstrates that the 
cells stored in the Biobank can really be used in experiments that include the use 
of molecules capable of inducing an increase of HbF. This will allow to set up 
experiments in parallel using cryopreserved cells from high number of patients in 
order to verify, among different HbF inducers, the best inducer for each patient, 
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using the cryovials stored in the Biobank without the need for repeated blood 
sampling. 
 
Figure 17 Comparison of the results obtained using protocol A and protocol C to culture the 
ErPCs for testing the MTH-erythroid induction. Cell samples were cultured and treated with 
MTH following two different methods: A= Fibach protocol, C= expansion protocol. The data of HbF 
(red) and α-globin peak (white) represent the increase, or the decrease respectively analyzed by 
HPLC in the untreated cells and in the treatedcells by MTH. 
 
In conclusion, the results reported in Figure 17 show that the method of cell 
expansion (protocol C) is effective to evaluate the increase of HbF levels following 
treatment with MTH. To further validate the data obtained by HPLC analysis, we 
decided to conduct a second set of analyses evaluating the increase of γ-globin 
mRNA in 9 patients by quantitative RT-qPCR. Also in this case, comparison 
between the two methods of cell culture (protocol A and protocol C) was 
performed. In the upper part of the panels displayed in Figure 18 we have 
reported the data obtained from the samples treated with MTH (T) in relation to the 
untreated sample (UNT). Both values of T and UNT samples were normalized 
calculating the ratio γ-globin/α-globin mRNA. As we can see, MTH induces 
increase of γ-globin transcript occurs with both methods of culture. In conclusion, 
the biobanked samples, cultured with Protocol C, have produced excellent results 
on γ-globin increase following treatment with MTH, supporting the hypothesis of 
being able to use the cells stored in Biobank for the study of HbF hemoglobin 
inducers. 
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Figure 18 . Comparison of ErPcs coltured with protocol A and C induced to erythroid 
differentiation by MTH. The data resulted from the analyses carried out on the cells obtained from 
9 different patients and cultuted with protocol A are picted in blue and with protocol C in red. In the 
upper part of the two panels, the increase of γ-globin/α-globin mRNAs is analyzed by RT-qPCR in 
MTH-treated cells with respect to untreated cell. In the middle and bottom, the normalized data of 
HbF and α-globin peak are reported and analyzed by HPLC on the same samples.   
 
For each of the 9 treated cellular cultures, HPLC analysis was also carried out. In 
the central part of the two panels in Figure 18 we have reported, in form of 
histograms, the percentage of HbF increase of the treated samples (T) compared 
to untreated (UNT) normalized according to the algorithm [(%HbFT-% 
HbFUNT)/(100-%HbFUNT)]. This data normalization allows us to evaluate how 
much the HbF increase is significant relative to its "potential maximum increase". 
As we can see when protocol C was used, the increase of HbF in the 9 cellular 
cultures treated with MTH results much more evident than the increase achieved 
with protocol A. Remarkably, however, cellular cultures derived from patient Fe15 
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did not show any increase of HbF when both protocols are used, suggeting that 
the precursor cells from this patient are not sensitive to MTH treatment. 
Finally, at the bottom of the two panels results are reported demonstrating that the 
increase of HbF hemoglobin is inversely correlated with a decrease of the α-globin 
peak. Also, in this case, the data reported are represented as the ratio of T/UNT 
samples normalized as previously described for HbF. 
In the graphs (the middle and bottom of the panels) shown in Figure 8, the inverse 
correlation between HbF and α-globin peak, it’s very clear in the cell samples 
isolated and cultured with the expansion protocol (protocol C). In fact, we can 
easily see that in the cultures derived from patients Fe10, Fe28, Fe50, AVLTH, 
AVLT21 a substantial increase of HbF hemoglobin always corresponds to a 
substantial decrease of the α-globin peak. 
In conclusion, the experiments described in this chapter have provided numerous 
confirmations about the possibility of using the cells stored in the Biobank for 
experiments on HbF hemoglobin induction.  
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6. Use of protocol A and protocol C with different HbF inducers. 
In addition to mithramycin, we wanted to test other HbF inducers comparing the 
two protocols (protocol A and protocol C); also, in this case the results of  the 
HPLC analysis were normalized using the previoulsly described algorithm 
[(%HbFT-%HbFUNT)/(100-%HbFUNT)] and all the treated samples were related 
to the untreated sample, originating from cultures performed in the absence of 
HbF inducers. In Figure 19 the cell cultures performed using cells from different 
patients are indicated by different colors (each color correspond to cell cultures 
from a same patient). We comparatively used four different HbF inducers: MTH, 
Hydroxyurea, Resveratrol and Butyrate, represented in the figure with differernt 
symbols. After comparing the data obtained during the experiments of HbF 
induction performed using protocol A and protocol C, we obtain a relationship that 
deviates a little from the line trend (R2=0,6). Some data obtained do not show an 
optimal correlation between the two protocols, but we have to consider that there 
are several variables, which can affect the treatment response.  
 
Figure 19 Comparison of the results obtained using protocol A and protocol C to culture the 
ErPCs and treated with HbF hemoglobin inducers. The HbF inducers Mithramycin (circle), 
Hydroxyurea (square), Resveratrol (rhombus) and Bytyrate (triangle) are indicated by different 
symbols and the patients are picted using different color. The comparison regard the HbF analyzed 
by HPLC made respectively using protocol C and protocol A to perform cell cultures (as reported in 
the axis of graph). 
For example, patients with different genotypes can be sensitive to the HbF 
inducers action in a different manner, depending on the cell culture system 
employed; we must also consider that the HbF inducers used are acting with 
84 
 
different mechanisms of action. All these factors can contribute to the expected 
(although limited) variability in response. 
 
7. Analysis with HbF hemoglobin inducers.   
So far, we have shown that cell samples stored in the cellular Biobank, despite 
undergoing the step of freezing shock, are suitable for evaluating the HbF increase 
following treatment with HbF inducers in a fairly comparable manner when 
induction pattern obtained with protocol A and protocol C are compared.  
At this point we wanted to investigate the extent to which the genotype of each 
patient could affect the HbF hemoglobin production after treatment with MTH. We 
have selected cells originating from some patients with β+ genotypes and other 
originating from patients with β0-thalassemia genotypes. All the cell samples used 
in the induction assay with MTH were from the cellular Biobank. 
The upper part of Figure 20 shows the data obtained by RT-qPCR. An increase in 
the γ-globin mRNA levels was obtained from the treated relative to untreated 
samples. All the data were normalized in relation to the α-globin. 
 
Figure 20 MTH induction of erythroid differentiation on ErPCs obtained from blood 
collection of patients with different genotype and cultured with protocol C. The ErPCs from 
patients with β+-thalassemia (n=7, white) and β
0
-thalassemia (n=12, black) were treated with MTH 
used as HbF inducer. In the upper panel, the data of RT-qPCR are reported and in the lower panel, 
the normalized values of HbF obtained by HPLC analysis. The mean value for the tow groups are 
also reported. 
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We selected from the Biobank 12 thalassemia patients with β0 genotype and 7 β+-
thalassemia genotype patients. As can be seen from the table, the average 
increase of γ-globin mRNA in the cells from β0 patients is higher than the average 
increase in the cells obtained from β+ patients. In the same experiment was also 
conducted an HPLC analysis. In this case, we analyzed 10 β0 patients, and 6 β+ 
patients. 
The data obtained from HPLC analysis are reported, as it was done in the previous 
sections, comparing treated cells with untreated cells and were normalized using 
the previously decsribed algorithm [(%HbFT-%HbFUNT)/(100-%HbFUNT)]. The 
results obtained from this analysis confirm that cells from β0-thalassemia patients 
show an increase of HbF greater than the cells from β+-thalassemia genotype 
patients. In general, we can assert that these data are in line with what we have 
discussed in the previous paragraphs. 
 
8. HbF hemoglobin inducers tested in cellular Biobank. 
The HbF hemoglobin increase in cell samples treated with known inducers was 
validated by RT-qPCR  and HPLC analysis using cells induced in protocols A and 
C. Accordingly, we decided to continue our investigation by focusing exclusively on 
the biobanked cells induced with protocol C. 
We selected 13 cell samples from patients with different genotype. Each sample 
was treated with the HbF inducers MTH and Hydroxyurea in parallel (Figure21). 
 
 
Figure 21 Comparison of induction of erythroid differentiation on ErPCs using MTH versus 
Hydroxyurea. Cell cultures from 13 patients were inducerd to erythroid differentiation both with 
MTH (green) and with Hydroxyurea (red). The data of HbF are reported and normalized with 
[(%HbF treated -%HbF untreated)/(100 - %HbF untreated)] algorithm.   
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The HPLC data were normalized as usual with the algorithm [(%HbFT-
%HbFUNT)/(100-%HbFUNT)]. As we can see the best inducer was Hydroxyurea 
versus MTH respectively in 6 and 5 cellular samples. However, MTH reached very 
high levels of HbF induction in AVLTF and AVLTT cellular samples, both with β0-
thalassemia genotype. This confirms what we had previously obtained (Figure20) 
using β0-thalassemia cellular samples that shown an HbF induction efficiency 
higher compared to β+-thalassemia samples. Finally, two cell samples did not 
responde to both treatments. The same experiment was performed in 8 cellular 
samples in which we compared the HbF inducers MTH and Resveratrol. In Figure 
22 we can see that the cases in which we obtained an HbF induction were 4 
samples treated with MTH against 3 samples treated with Resveratrol. A single 
sample showed an HbF increase level slightly lower than the baseline. In this 
experiment, the highest HbF increase was obtained again with MTH inducer in the 
Fe46 cellular sample having a β0-thalassemia genotype.  
 
 
Figure 22 Comparison of induction of erythroid differentiation on ErPCs using MTH versus 
Resveratrol. Cell cultures from 8 patients were inducerd to erythroid differentiation both with MTH 
(green) and with Resveratrol (blue). The data of HbF are reported and normalized with [(%HbF 
treated -%HbF untreated)/(100 - %HbF untreated)] algorithm.   
 
The conclusion of this set of experiments is that a great patient-to-patient 
variability is expected, as the cells from different patients are susceptible in 
different way to the HbF inducers. This can be associated to the patient's clinical 
status at the time of blood sampling and to the genetic characteristics of each 
patient.  
The lack of response to some HbF inducers, when confirmed, strongly suggest 
that this apprach is needed to design personalized therapy. 
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Discussion 
 
The knowledge on the human genome and of the molecular mechanisms involved 
in different diseases allows to completely rebuild medical practices and to review 
and futher develop classic treatment approaches. More and more frequently we 
talk about personalized medicine, which starts from specific molecular and genetic 
characteristics of a patient and ends in the deliver the most appropriate therapy. 
The general consensus on this specific issue is that it would be very useful to 
identify the best therapy for each patient by integrating all obtained data from an 
individual patient, and comparing them with the clinical information available for 
other patients (Kohane 2011). The need to gather information and biological 
material collected for patients to conduct studies of predictive nature, led to the 
establishment of new complex structures called Biobank (Khleif, Doroshow et al.; 
and Fiore D'Avolio 2011). A biobank is a systematic collection of biological 
samples (for instance genomic DNA, RNA, protein, cellular pellets) fully organized 
and containing also the information about the state of health of each participant 
(Hewitt 2011; King 2011) 
It is in this context that the research conducted in this PhD Thesis took place. In 
detail this research activity has been conducted in the context of a multicenter FP7 
European Project called THALAMOSS (THalassemia MOdular Stratification 
System), having as major objective the identification of molecular markers 
facilitating the development of personalized therapies for hemoglobinopathies, in 
particular β-thalassemia.  
The β-thalassemias are autosomal recessive genetic disorders caused by the 
absence or reduction of β-globin chains (Silvestroni and Bianco 1948; Clegg and 
Weatherall 1999; Canali 2008). The β-thalassemia patients are treated with 
periodic blood transfusions associated to the assumption of iron chelating drugs 
and/or, when possible, with bone marrow transplantation (BMT) (Lucarelli, 
Galimberti et al. 1998). Despite scientific advances aimed at the development of 
targeted and definitive treatments of the disease, a cure of β-thalassemia is, at 
present, not available.  
Originally described in the Mediterranean area (Haldane 1949), β-thalassemia 
should be at present considered a worldwide pathology with more than 100,000 
new cases annually (Galanello and Origa 2010) and with a high incidence 
especially in countries belonging to Africa and Central and Southeast Asia. The 
88 
 
frequent and significant migration flows that have occurred over the decades have 
contributed irreversibly to the wide distribution of the disease (Flint, Harding et al. 
1998). In Italy, the most affected areas are Sicily, the delta of the river Po and 
Sardinia, with an incidence of approximately 95.7% (Silvestroni, Bianco et al. 
1950; Hill 1987; Rosatelli, Dozy et al. 1992; Canali 2008). 
THALAMOSS is aimed at the development of a computerized system that enables 
β-thalassemia patient stratification according to clinical, genetic and molecular 
features in order to implement a personalized therapy.  
Before the collection of biological samples, the approval by the Ethics Committee 
of Ferrara and Verona-Rovigo district was obtained. All the subjects, who have 
contributed to the establishment of the cellular Biobank, gave their positive 
consent. 
The cellular Biobank that was established thanks to the experimental activities 
described in this PhD thesis, is at present composed of cells obtained from 75 
subjects, most of them being β-thalassemia patients who do not present 
alterations of α-thalassemia. In addition, a small fraction (11 subjects) is composed 
by cells from healthy subjects.  
The participants recruited originate in the province of Ferrara, some areas of 
Veneto; in sporadic cases, they originate from non-EU areas (individuals 
immigrants). The average age of the subjects was about 40 years and 
approximately 54.2% of the participants are women. Each subject adhering to the 
Biobank was genotyped in our laboratory at the Ferrara University for what refers 
to the β-globin gene, while the analysis of some HbF related polymorphisms were 
carried out at the Regional Hospital for Microcytemia in Cagliari. (Figure 6-8). 
From the β-globin gene characterization it can be concluded that the genotypes 
present mainly are those most common in the geographic areas of origin, i.e. 
β039/β039, β+IVSI-110/β039 and β+IVSI-110/ β+IVSI-110, present with a percentage 
of 30%, 22% and 11%, respectively. Instead, analysis of HbF-associated 
polymorphisms revealed that rs10189857 (A/G) is the most prevalent BCL11A 
polymorphism and XmnI rs74482144 (+/-; +/+) polymorphism exhibit low frequency 
in the biobanked samples. Almost half of the patients (47%) is a carrier of a 
HBS1L-Myb rs9399137 (T/C) polymorphism. 
To date, there are already biobanks operating, directly or indirectly, in the field of 
thalassemia. They take care of collecting and preserving DNA, in order to conduct 
genetic investigations, as well as and others cellular samples, such as T-
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lymphocytes, fibroblasts and lymphoblasts. However, at present, at the best of our 
knowledge, no Biobanks are present composed of the hematopoietic stem cells 
isolated from peripheral blood and cryopreserved, in order to be ready any time for 
conducting studies on thalassemia.  
In the construction of a cellular Biobank, several major problems can be 
encountered, such as the low number of circulating hematopoietic stem cells, and 
the possible inability of these cells to return viable after the freezing step and the 
cryopreservation period. This specific issues were the major objects of our 
research activities.  
Several efforts were focused on overcoming a number of important issues related 
to the culture systems of these cells. First of all, we have selected the CD34+ cells 
from a peripheral blood sample using two methods in succession. Ficoll Hipaque 
allows to separate the different components of whole blood according to the 
density gradient. In particular, we isolated lymphocytes, macrophages, fibroblasts 
and erythroid precursor cells from the remaining cellular blood components. Then 
we applied on this heterogenous cellular population the MACS Method (Magnetic 
Assay Cell Sorting). This method uses magnetic microbeads having a surface 
structure that can recognize and selectively bind CD34+ cells (Watanabe, Kawano 
et al. 1999; Wang, Hsu et al. 2001; Zuccato, Breda et al 2012).. This step allows to 
set up very pure cell culture. At this point, we have tried to increase the cellular 
concentration by using an expansion culture medium. For the development of the 
expansion medium for optimal growth of CD34+ cells a protocol described for the 
first time by Leberbauer was employed (Leberbauer, Boulme et al. 2005). This 
medium was later modified by Breda and Rivella, who have employed it in studies 
for β-thalassemia treatment with the gene therapy method (Breda, Casu et al 
2012). This medium contains StemSpan Serum-Free Medium Expansion, 
StemSpan® CC100 Cytokine Cocktail for expansion of human hematopoietic cells 
stem cell, erythropoietin (EPO), dexamethasone 21-phosphate disodium salt and 
PEN-STREP.  
In order to verify the suitability of this approach for studies on β-thalassemia, we 
have firstly evaluated the ability of this medium to stimulate the cell growth without 
influencing their natural differentiation state; then we decided to use this culture 
medium during CD34+ cells expansion phase and after thawing cryopreserved 
packed cells. 
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From each blood sample, we can obtain an average of about 5 aliquots 
(5x106cells/mL) of CD34+ cells for each patient. It is important to obtain this 
minimal quantity of cells in order to conduct functional studies (including proteomic 
and transcriptomic analyses) using cells stored in the cellular Biobank. This is of 
course of great interest not only for the scientific community, but also for the 
patients involved in this activity. In fact, this approach, unlike the two-phase culture 
system developed by Fibach, allows experimentation without the necessity of 
repeated sampling from the patients. After having developed protocols for 
isolation, expansion and storage of CD34+ cells, we have decided to validate the 
experimental method by evaluating different cellular parameters important in the 
field of drug development for β-thalassemia. 
In order to assess what impact the freezing step and the cryopreservation could 
have on our cellular cultures we have thawed cells from 36 of the 75 subjects of 
cellular Biobank with different thalassemia mutation/phenotype: β+, β0, β+/β0 and 
HbS/β0 (Figura10) The degree of erythroid differentiation was evaluated by a 
benzidine assay  4 days and 9 days after thawing; in all cellular cultures analyzed 
an increase of the percentage of B+ cells was observed. Confirmation of cell 
viability and cell differentiation efficiency was obtained by analyzing cellular 
samples for hemoglobins production by HPLC analysis (Huisman 1987) (Figura 
11). The data obtained allowed us to conclude that freezing, crypreservation and 
thawing steps performed do not affect the natural erythroid differentiation process.  
As a confirmation of the cell samples stability stored in the biobank, the 
chromatograms obtained by HPLC analyses of several cell samples derived from 
β-thalassemia patients with different genotypes, show that hemoglobins retain a 
similar trend in the various moments of the culture (Figure12). 
To determine whether our cellular samples collected in the Biobank can really be 
used to conduct several experiments with different approaches in an indeterminate 
period of time, we have investigated whether the freezing of the cells for a long 
time could have significant effects on the hemoglobin pattern. Two cells aliquots 
from the same patient deriving from the same blood collection, were thawed after 
several months one from the other and we have evaluated the globin pattern in the 
two moments by HPLC analysis (Figure13). The hemoglobins trend in both 
experiments is perfectly superimposed showing that cryopreservation does not 
alter the erythroid differentiation potential of the cells stored in cellular Biobank.  
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In order to create a Biobank containing numerous cell samples for each subject 
suitable to conduct several experiments any time, we verified that the cells 
obtained with several samplings from the same patient exhibit a same pattern of 
hemoglobin production. To this aim, we selected some patients, we cultured cells 
isolated from two different withdrawals and finally we evaluated the hemoglobin 
pattern (Figure14). The results obtained confirmed that the pattern of hemoglobin 
poduction was found to be the same in all cellular samples analyzed and deriving 
from the same patient.  
The conclusion of this first set of results is that the culture system employed for the 
generation of the cellular Biobank does not alter the kinetics and the type of 
hemoglobin produced by the cells from a same patient, after freezing, 
cryopresenvation and thawing.  
However, an important feature of the cellular Biobanks involves the possibility of 
sending multiple cellular aliquots in different parts of the world in order to conduct 
predictive experiments to identify the best therapeutic approach for a given patient 
or patients subgroups. To verify this important issue, we performed experiments in 
parallel with the Weil Medical College of Cornell University in New York. Aliquots of 
cells from different patients isolated and frozen at the Ferrara University were sent 
to New York, and same experiments were done in duplicate with the same cellular 
cryopreserved samples. The results demonstrate that we have the real possibility 
of sending cellular aliquots of the Biobank to different laboratories of the world to 
conduct experiments on pre-validated samples (Figure 15 and 16). 
Finally, an important goal of our experiments was to determine whether the cellular 
Biobank can be employed to identify and develop in vitro HbF inducers, already 
demonstrated to be a very effective therapeutic strategy for treatment of β-
thalassemia. This is not a resolutive approach of the disease but greatly improves 
the clinical status of the β-thalassemia patients.  
In the past, several erythroid cell lines have been used extensively as 
experimental model system to study β-thalassemia and to develop new 
therapeutic strategies. Until today, the erythroid cells were cultured either in semi-
solid medium, where they develop into discrete colonies, or in liquid medium 
where they grow as single cells or clusters in suspension (Myers, Katz et al. 1984; 
Fibach, Manor et al. 1989; Leimberg, Konijn et al. 2003; Fibach and Prus 2005). In 
all these systems erythropoietin (EPO) is essential for full development of 
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hemoglobin containing erythroid cells (Box et al., 1996; Fibach, Bianchi et al. 
2003).  
In determining possible applications of the cellular Biobank we have developed, an 
important issue was to compare the cells stored in the biobank obtained with our 
expansion protocol (protocol C) with the cells cultures following the Fibach 
protocol (protocol A), with respect to the ability to increase HbF levels. We 
selected some cellular samples with different genotypes representative for the 
Biobank. The cells were maintained in culture in parallel following the procedures 
and times provided for the two culture methods and then were treated with 
different HbF inducers, including mithramycin (MTH) (Bianchi, Osti et al. 1999; 
Fibach, Bianchi et al. 2003), resveratrol (RSV) (Bianchi, Zuccato et al. 2009; 
Fibach, Prus et al. 2012), butyric acid (BA) (Perrine, Ginder et al. 1993; Sher, 
Ginder et al. 1995). and hydroxyurea (HU) (Bradai, Abad et al. 2003; Alebouyeh, 
Moussavi et al. 2004), considered at the reference compounds because it is 
already under clinical usage for β-thalassemia and sickle-cell disease.  
The conclusion of these experiments, reported in detail in Figures 17 suggest that 
when the cells have been cultured with Protoc C, they exhibit and “endogenous” 
starting HbF level higher than those obtained with the two-phase protocol A (the 
Fibach method). Despite this, in all cases it is possible to appreciate an increase in 
the HbF production with the different treatments and correlated with a reduction of 
the α-globin peak. The data obtained were then validated by RT-qPCR analysis 
(Figure18). This experiment allowed us to demonstrate that the cells stored in the 
biobank are responsive to treatment with HbF inducers albeit starting from higher 
HbF levels.  
All data obtained confirm the potential use of the cellular biobank to conduct 
studies with HbF hemoglobin inducers. Considering that the cellular Biobank was 
set up starting from subjects genotypically different, we decided to investigate 
whether two different genotypes produce different induction effects following the 
mithramycin treatment. The experiments conducted by RT-qPCR and HPLC 
analysis showed that the cryopreserved cells obtained from β0-patients display an 
increase of HbF greater than the cells obtained from β+-thalassemia patients 
(Figure20).  
The conclusion of the final set of experiments performed with different inducers on 
cryopreserved cells cultured with protocol C is that a great patient-to-patient 
variability is expected, as the cells from different patients are susceptible in 
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different way to different HbF inducers (Figure 21-22). This can be associated to 
the patient's clinical status at the time of blood sampling and to the genetic 
characteristics of each patient. Finally, the lack of response to some HbF inducers, 
when confirmed, strongly suggest that this apprach is needed to design 
personalized therapy.  
The possibility to conduct pre-clinical testing on the cells of a patient stored in the 
cellular Biobank represents an immense resource for researchers and patients. 
Evaluate the response to innovative treatment in a timely manner provides 
essential information for researchers who in this way can evaluate the effects 
caused by the drug, and represents a protection for the patient by limiting the 
administration only for potentially curative molecules.  This research activity will 
allow patients stratification taking into account all the phenotypic/genotypic 
characteristics of the single individual in association with in vitro HbF induction 
under treatment with effective inducers. 
Further, the cellular Biobank can provide cell from different patients for the 
construction of induced pluripotent cells (iPS) for single patients. This is a great 
opportunity, when considered together the possibility of gene editing, leading to 
the correction of the genetic mutation by several approaches, including gene 
therapy and the use of strategies for homologous recombination. 
We should point out that gene therapy is one of the most promising approaches 
for future management of the β-thalassemia patients. The most direct strategy of 
gene therapy aims at substituting the non-functioning endogenous β-globin genes 
with a normal β-globin gene carried by lentiviral vectors, thus obtaining de novo 
production of adult haemoglobin (HbA). In this case two gene therapy approaches 
have been demonstrated to be efficient, based on the use of lentiviral vectors 
carrying the human γ-globin gene sequences (in this case HbF is produced by an 
exogenously added γ-globin gene), or carrying sequences coding for artificial 
promoters of the γ-globin gene (in this case HbF is produced by inducing 
transcription of the silent endogenous γ-globin genes). In addition, novel 
therapeutic approaches have been recently validated, such as nuclease-mediated 
gene editing by homologous recombination of the human globin locus. In this 
case, correction of altered β-globin genes can be achieved. Endogenous genomic 
loci can be altered efficiently and specifically using engineered zinc finger 
nucleases (ZFNs) and transcription-activator-like effector nucleases (TALENs). 
Moreover, besides ZFN and TALEN, clustered regularly interspaced short 
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palindromic repeats (CRISPR) linked to Cas9 nuclease are now also being 
investigated for their utility in modifying β-globin. 
As far as the cellular targets of gene therapy, human erythropoietic stem cells have 
been considered in most studies; however in the future we expect that induced 
pluripotent stem cells (iPSCs) from β-thalassemia patients will be also a useful 
cellular target of GT approaches. The cryopreserved biobanked cells can be a very 
important biological sources for these experiments. 
As a final comment, Biobanks can provide a huge opportunity for development, 
research and knowledge and the beneficiaries will be all human beings and all 
future generations (An 2006). It is now clear the decisive role of Biobanks to 
accelerate scientific discoveries. To maximize results it is important to dedicate 
attention to the quality of numerous samples collected in the biobanks, to the 
creation of a partnerships network and to financial infrastructures.  
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Appendix 1. Distribution of main biobanks spread around the world. 
 
European Biobanks 
 
State City Biobank name 
AT Graz Biobank Graz 
AT Graz BioResurce-Med 
AT Graz LifeCord Public Cord Blood Bank 
AT Krems an der 
Donau 
Cells and Tissue Bank Austria 
AT Wels European Cell and Tissue Bank 
AT Österreich VITA 34 GmbH Österreich 
AT Vienna MUW Biobank 
AT Vienna Ludwig Boltzman Tumour Bank 
AT Vienna Vitacord, Gesellschaft für Stammzellenlagerung m.b.H 
BE Brussels SaintLuc Tumour Bank 
BE Brussels Tissue Bank of the University Hospital Saint Luc 
BE Liege GIGA-BIOBANK 
BE Liege Belgian Cord Blood Bank 
BE Luxembourg Integrated Biobank of Luxembourg 
BG Sofia National DNA Bank of the Republic of Bulgaria 
BG Sofia Tissue Bank Pirogov 
CH Bern Biobank Suisse 
CH Pfaeffikon CryoSave 
CH Bern Tumor Bank Bern 
CH Geneva East West Biopharma 
CH Monthey Swiss Biobank 
CY Limassol StemCure 
DE Berlin Central Biomaterial Bank -
 German Heart Failure Network 
DE Berlin Tissue Bank, Charité – Universitätsmedizin 
DE Berlin SepNet Central Sample Bank 
DE Düsseldorf Jose Carreras Cord Blood Bank  
DE Heidelberg Patient DNA collection at Institute of Human Genetics 
DE Heidelberg Human Melanoma Biobank 
DE Munich BrainNet Europe 
DE Munich KORAgen 
DE Regensburg Danubian Biobank Consortium 
DE St. Ingbert Kryoforschungs- & Demonstrationsbank der Fraunhofer 
Gesellschaft “Eurocroyo SAAR” 
DE Tübingen European Searchable Tumour Line Database 
(ESTDAB) 
DK Copenhagen The Danish National Birth Cohort 
DK Copenhagen The National PKU Biobank 
DK Copenhagen NUGENOB 
DK Copenhagen The Danish Psychiatric Biobank 
DK Copenhagen The Danish National biobank 
EE Tartu Estonia Biobank 
ES Barcelona Biobank of Hospital Clínic  IDIBAPS 
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ES Granada Andalusian Regional Tumour Bank 
ES Madrid HIV Biobank 
ES Madrid Spanish National Tumour Bank Network 
FI Helsinki National Biobank of Finland 
FI Helsinki The Finnish Biaobank 
FI Tampere Helsinki Sudden Death Study (Tampere University) 
FI Turku Biobanking and Biomolecular Resources Research Infr
astructure Institute BBMRI 
FR Amiens Biobanque de Picardie 
FR Evry Genethon DNA and Cell Bank 
FR Lyon Biobank Resource Centre de France 
FR Lyon European Sarcoma & Tumour Bank 
FR Marseille Tumour Bank of Provence 
FR Toulouse Southwest France Tumour Bank 
GR Athens Hellenic Cord Blood Bank 
GR Marousi StemHealth Hellas Stem Cell Bank 
HU Budapest Hungarian NeurologicalPsychiatric Biobank 
HU Budapest KRIO Institut 
HU Pecs National Biobank Hungarian 
IE Dublin Biobank Ireland Trust 
IE Dublin Dublin Brain Bank 
IE Belfast Northern Ireland Virtual Tissue Archive 
IE Wexford Biostor Ireland 
IE Trinity Trinity Biobank 
IS Reykjavik Icelandic Biobank (deCode) 
IS Kópavogur The Icelandic Cancer Society Biological Specimen 
Collection 
IS Reykjavik Tissue Archives, University Hospital in Reykjavik 
IT Florence daVinci European Biobank 
IT Genoa Biological Resource Centre -
 National Institute for Cancer Research 
IT Genoa Telethon Genetic Biobank Network 
IT Milan BioRep 
IT Milan Movement Disorders Biobank 
IT Milan Istituto Nazionale Neurologico Carlo Besta 
IT Milan The Neuromuscular biobank, Department of 
Neurological Science, University of Milano 
IT Milan Bank of DNA cell line and nerve-musclecardiac disease 
IT Naples Naples Human Mutation Bank of the Cardiomyology 
and Medical Genetics (NHGMB) 
IT Padua EuroBioBank 
IT Siena Cell lines and DNA bank of Rett syndrome, X-linked 
mental retardation and other genetic diseases 
LV Riga Latvia Biobank 
MT Malta Malta BioBank 
NL Groningen ErasmusMC 
NL Groningen Lifelines Biobank 
NL Rotterdam European Human Frozen Tissue Bank 
NL  TuBaFrost 
NL Maastricht BioBank Maastricht 
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NL Amsterdam Blood bank of rare blood groups of the Council of 
Europe 
NO Levanger Hunt Biobank 
NO Trondheim Regional Biobank of Central Norway 
NO Rockville JANUS Serumbank (Cancer Registry of Norway) 
NO Bergen HUSK (Health Study of Hordaland) 
NO Oslo MoBa (The Norwegian Mother and Child Cohort Study) 
RO Bucharest Spitalul-clinic Colentina 
RO Bucharest Medsana Bucharest Medical Center 
RO Bucharest University Hospital “Panait Sarbu” Bucharest Assisted 
Reproduction Departmen, Sperm Bank,Embryo Bank 
RO Timisoara IVF Center “Victor Babes” University of Medicine and 
Pharmacy 
SE Lund Swedish Regional Biobank 
SE Malmo European Cancer Biobank 
SE Stockholm Karolisnka Biobank 
SE Stockholm LifeGene 
SE Stockhom Swedish National Biobank Program 
SE Umea Biobank of Northern Sweden 
SE Birmingham Central England HaematoOncology Research Biobank 
SK Bratislava Eurocord Slovakia 
UK Cambridge CamUroOncology Biobank 
UK Cambridge Geneservice 
UK Cardiff Wales Cancer Bank 
UK Dundee Tayside Tissue Bank 
UK Edinburgh Edinburg Brain & Tissue Banks 
UK Glasgow Biopta 
UK Hertfordshire onCore UK 
UK Hertfordshire UK Stem Cell Bank 
UK Leicester Children's Cancer and Leukaemia Tissue Bank 
UK Liverpool Cancer Tissue Bank Research Centre 
UK London Chernobyl Tissue Bank 
UK London Confederation of Cancer Banks 
UK London King's College Infectious Diseases BioBank 
UK London Neuroendocrine Tumors Biobank 
UK London UK Parkinson's Disease Tissue Bank 
UK London UK Multiple Schlerosis Tissue Bank 
UK London Virgin Health Bank 
UK Manchester UK DNA Banking Network 
UK Midlothian Roslin Wellcome Trust Tick Cell Biobank 
UK Newcastle Upon 
Tyne 
HDBR  Human Developmental Biology Resource 
UK Oxford Autism Brain Bank 
UK Plymouth BioVault 
UK Salisbury European Collection of cell Cultures 
UK Southampton Southampton Tumour Bank 
UK Stockport UK Biobank 
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Canada Biobanks 
 
City Biobank name 
Edmonton Canadian Biosample Repository 
Edmonton Alberta Research Tumor Bank 
London Lawson Brain Tumour Tissue Bank 
Manitoba Manitoba Breast Tumor Bank 
Montreal CARTaGENE 
Montreal Quebec Leukemia Cell Bank 
Montreal Tissue Bank of the Respiratory Health Network of the FRSQ 
MontRoyal PROCURE Quebec Prostate Cancer Biobank 
Ottawa Canadian Study on Health and Aging 
Toronto Canadian Virtual Brain Tumour Network 
Toronto Ontario Tumour Bank 
Toronto Blood Borne Pathogens Laboratory 
Toronto Sunnybrook Tumour Bank 
Vancouver British Columbia Breast Cancer Tumour Bank 
Vancouver British Columbia Gynaecologic Tissue Bank 
Vancouver British Columbia Tumour Tissue Repository 
Winnipeg Canadian Tumour Repository Network 
Winnipeg Manitoba Breast Tumour Bank 
 
US Biobanks 
State City Biobank name 
AL Birmingham University of Alabama Tissue Collection and Banki
ng Facility 
AL Hunstville Conversant Biologics, Inc. 
AZ Tucson Arizona Cancer Center Tumor Bank 
AZ Sun City Banner Health Brain & Tissue Bank 
AZ Phoenix Arizona Biospecimen Locator 
AZ Phoenix ScienceCare 
CA San Francisco AIDS & Cancer Specimen Resource 
CA Los Angeles Autism Tissue Program 
CA Monterey Biobanc USA 
CA Fullerton BioOptions 
CA Los Angeles California Cryobank, Inc. 
CA Van Nuys HemaCare Corp. 
CA Loma Linda Loma Linda University Cancer Center Biospecime
n Laboratory 
CA Los Angeles National Neurological AIDS Bank 
CA San Francisco PathServe 
CA South San Francisco  Cureline 
CA Solana Beach PrecisionMed 
CA Romona Protein Technologies 
CA Santa Monica Sanguine BioSciences, Inc. 
CA Palo Alto Stanford Tissue Bank 
CA Berkley UC Berkley Biorepository 
CA Sacramento UC Davis Biorepository 
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CA San Diego UC San Diego Biorepository 
CA Los Angeles UCLA Brain and Spinal Fluid Resource Center 
CA San Francisco UCSF AIDS Specimen Bank 
CA San Francisco UCSF Brain Tumor Tissue Bank 
CA Mission Bay UCSF DNA Bank 
CA San Francisco UCSF Specimen Banking Core 
CA Westlake Village Coreva Human Milk Bank 
CO Aurora Beryllium BioBank 
CO Aurora Rocky Mountain MS Brain Tissue Bank 
CO Nederland Donor Sibling Registry 
CT Farmington Research Tissue Repository -
 University of Connecticut 
CT Norwalk Myeloma Tissue Bank 
DC Washington Genetic Alliance Biobank 
DC Washington PXE Internatonal Tissue Bank 
FL Boynton Beach International Biobank, Inc. 
FL Gainesville Barth Syndrome Biorepository 
FL Tampa LifeLink TissueBank 
FL Tampa M2Gen Biorepository 
FL Gainesville University of Florida DNA & Tissue Bank 
FL Gainesville University of Florida Molecular Tissue Bank 
FL Coral Gables University of Miami Biorepository 
FL Coral Gables University of Miami Brain & Tissue Bank for Devel
opmental Disorders 
FL Coral Gables University of Miami Tissue Bank 
GA Atlanta Biorepository Alliance of Georgia for Oncology 
GA Augusta Medical College of Georgia Tumor Bank 
IL Chicago University of Chicago Human Tissue Center 
IN Indianapolis BioStorage Technologies 
IN Indianapolis National Gene Vector Biorepository 
IN Indianapolis Susan G. Komen Tissue Bank 
LA New Orleans Ochsner Tumor Tissue Bank 
MA Boston Brighman & Women'sHarvard Biobank 
MA Boston Dana Farber Tissue Bank 
MA Cambridge Harvard Brain Tissue Resource Center 
MA Lexington StoreaTooth Stem Cell Bank 
MA Pepperell Masy Systems 
MA Waltham Accelerated Cure Project MS Repository 
MA Boston Crimson Biospecimen Core 
MA Boston National Temporal Bone Pathology Resource Reg
istry 
MA Milford SeraCare Lifesciences 
MA Peabody Progeria Cell & Tissue Bank 
MA Norton ProMedDx 
MA Worcester University of Massachussets Cancer Tissue Bank 
MA Shrewsbury University of Massachussets Stem Cell Bank 
MA Waltham Multiple Schlerosis (MS) Repository 
MD Rockville BioReliance Biorepository 
MD Beltsville Bioserve 
MD Rockville Capital Biosciences 
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MD Rockville Fisher BioServices 
MD Gaithersburg Genelogic 
MD Chestertown ILSbio 
MD Gaithersburg KamTek Biorepository 
MD Baltimore Maryland Brain Collection 
MD Frederick National Cancer Institute Biorepositories 
MD Bethesda Cooperative Human Tissue Network (CHTN) 
MD Bethesda NCI Office of Biospecimens 
MD Bethesda NIDDK Central Biorepository 
MD Rockville Origene 
MD Baltimore Tissue Banks International 
MD Baltimore University of Maryland Brain & Tissue Bank 
MD Rockville US Biomax 
MI Detroit Asterand 
MI Royal Oak Beaumont Hospitals Biobank 
MI Detroit JP McCarthy Cord Stem Cell Bank 
MI Detroit Michigan Neonatal Biobank 
MI Ann Arbor University of Michigan Biorepository 
MI Ann Arbor University of Michigan Human Breast Cancer Cell 
Lines 
MN Rochester Mayo Clinic Biobank 
MN Rochester Mayo Validation Support Services Biobank 
MN Rochester Mayo Mitochondrial Disease Biobank 
MN Minneapolis Minnesota Liver Tissue Cell Distribution System 
MN Minneapolis University of Minnesota Tissue Bank 
MO St Louis Washington University Tissue Bank 
NC Durham Duke Biospecimen Repository 
NC Durham Duke Biobank 
NC Durham Duke Cancer Tissue Bank 
NC Greensboro Chordoma Foundation Biobank 
NJ Princeton Autism Tissue Bank 
NJ Camden Coriell Stem Cell Biobank 
NJ Hackensack Hackensack University Tissue Bank 
NJ Edison Musculoskeletal Transplant Foundation 
NJ Piscataway Rutgers Cell & DNA Repository 
NY Syracuse Central New York Eye & Tissue Bank 
NY New York Columbia U Brain Bank 
NY New York Mantle Cell Lymphoma Cell Bank 
NY New York Manhattan HIV Brain Bank 
NY New York Mount Sinai Biobank 
NY New York New York University Specialty Tissue Banks 
NY New York StemSave 
NY Manhasset North Shore LIJ Biorepository 
NY Buffalo Roswell Park Biorepository 
NY Vestal CardioFacio-
Cutaneous Syndrome International Biobank 
OH Cleveland Case Western Biorepository 
OH Cincinnati Cincinnati Biobank Core Facility 
OH Cleveland Cleveland Clinic Genomic Medicine Institute 
OH Powell Folio Biobank 
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OH Columbus Ohio State Biorepository 
OH Columbus Ohio State Leukemia Tissue Bank 
OH Columbus Ohio Tissue Resource Network 
OH Athens Ohio U Diabetes Endocrine Biorepository 
OH Shaker Heights Cellular Technology Ltd 
OR Portland Oregon State Health Biolibrary 
OR Portland National Psoriasis BioBank 
OR Portland Oregon Brain Bank 
PA Philadelphia CHTN Eastern Division -
 University of Pennsylvannia 
PA Philadelphia Fox Chase Tumor Bank 
PA Danville Geisinger Biobank 
PA Philadelphia National Disease Research Interchange 
PA Pittsburgh National Surgical Adjuvant Breast and Bowel Proj
ect Tissue Bank 
PA Philadelphia University of Pennsylvannia Tumor Tissue Bank 
PA Windber Windber Tisue Bank 
RI Providence Rhode Island Biobank 
SC Greenville South Carolina Biorepository System 
SC Greenville Greenville Hospital System Cancer Biorepository 
SC Charleston University of South Carolina Biorepository 
TN Memphis World BioBank 
TN Nashville Vanderbilt Biobank 
TN Nashville Vanderbilt University (Cooperative Human Tissue 
Network) 
TX Austin BioEden Tooth Cell Bank 
TX Houston MD Anderson Clone Bank 
TX Houston MD Anderson Gynecologic Cancer Tissue Bank 
TX Houston MD Anderson Pancreas Tissue Bank 
TX Houston SeqWright Biorepository 
TX Houston Texas Medical Center Biobank 
TX San Antonio South Texas Tumor Bank 
TX Galveston University of Texas Tumor Bank 
VA Manassas ATCC 
VA Charlottesville University of Virginia Biorepository 
VA Fairfax Fairfax Cryobank 
VA Richmond UNOS Network for Organ Sharing 
WA Bainbridge Island Inflammatory Breast Cancer Biobank 
WA Seattle International Histocompatibility Cell and DNA Ban
k 
WI Milwaukee Aurora Healthcare Biorepository 
WI Marshfield Marshfield Clinic Biobank 
WI Madison National Stem Cell Bank 
WI Madison WiCell 
WI Milwaukee Wisconsin Tissue Bank 
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Mexican Biobanks 
State Biobank name 
Mexico Genomic variability and haplotype map of the Mexican 
population 
 
Asian Biobanks 
State Biobank name 
China Cancer Center Tissue Bank  Fudan University 
China Origene China 
China Taizhou Biobank 
India Bangalore Brain Bank 
India Narayana Hrudayalaya Tissue Bank and Stem Cell Research Center 
India Tata Memorial Hospital Tissue Bank 
India TCG Life Sciences Biobank 
India Dhruv Dental Stem Cell Bank 
Japan Biobank Japan 
Japan Japanese Collection of Bioresource Materials 
Japan Riken BRC Cell Bank 
Japan Tokyo Cord Blood Bank (Japanese) 
Korea Korean National Tissue Bank 
Korea Seoul Cord Blood Bank 
Malaysia CryoCord Stem Cell Bank 
Malaysia Malaysian Tissue Bank 
Malaysia StemLife Stem Cell Bank 
Singapor
e 
Singapore Biobank 
Singapor
e 
National University Tissue Repository 
Singapor
e 
Singapore Cord Blood Bank 
Singapor
e 
Singapore Tissue Network 
Singapor
e 
StemCord Cord Blood Bank 
Taiwan Taiwan Biobank (Chinese) 
Thailand Asia Pacific Association of Tissue Banking 
Thailand Bankok Biomaterial Center 
 
Australian Biobanks 
 
State Biobank name 
Adelaide Australian Prostate Cancer Tissue Bank 
Auchenflower Ventyx Wesley Research Institute Biobank 
Brisbane Queensland Children's Tumour Bank 
Carlton Victoria Victorian Cancer Care Biobank 
Chatswood Multiple Sclerosis Research Australia Brain Bank 
Clayton South ASPREE Healthy Ageing Biobank 
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East Melbourn
e 
Austrailasian Biospecimen Network 
Queensland Austrailasian Leukemia & Lymphoma Tissue Bank 
Randwick Australian Brain Bank 
Sydney Genetic Repositories Australia 
Sydney Westmead Paediatric Tumour Bank 
Westmead Australia Breast Cancer Tissue Bank 
Westmead CellBank Australia 
  
Middle East Biobanks 
 
State Biobank name 
Iran Iran National Tumor Bank 
Israel Sheba Medical Center Tissue Bank 
Israel Taburit Umbilical Cord Blood Bank 
Israel National Laboratory for the Genetics of Israeli Populations 
 
Animal & Plant Biobanks 
 
State Biobank name 
Austria VetBioBank 
Canada BC Fisheries Living Gene Bank 
Ecudaor Banco de datos de biodiversidad del Ecuador 
Germany EUPRIMNet Primate Biobank 
Israel Israel Plant Gene Bank 
Italy Global Crop Diversity Trust 
Japan Japanese Collection of Bioresource Materials 
Japan National Institute of Agrobiological Sciences Genebank 
Malaysia Renexus Group 
New Zealand Rare Breeds Gene Bank 
New Zealand NZ Rare Disease Biobank 
Norway Marbank  National Marine BioBank 
Norway Nordic Genetic Resource Centre (Animals & Forestry) 
Norway Svalbard Global Seed Vault 
Sweden Nordic Genetic Resource Centre (Plants) 
UK Rare Breed Survival Trust 
US Aged Rodent Tissue Bank 
US Alpha Genesis 
US Bioreclamation 
US Folio Mouse Biobank 
US KBar Livestock 
US Magellan Bioscience Group 
US Marine Mamal Tissue Bank 
US Mouse ES Stem Cell Bank 
US NCI National Products Branch 
US SVF Foundation 
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Appendix 2. All subjects (patients and healthy subjects) collected in biobank in 
table are listed. For each of them an identification code and the genotype beta 
globin are given. Only in β-thalassemia patients polymorphisms HPFH related 
known were investigated 
 
CODE GENOTYPE 
BCL11A 
rs1427407 
BCL11A 
rs10189857 
HS1L-
cMYB 
rs9399137 
XmnI 
rs7482144 
Fe3 β
+
IVSI-110/β
+
IVSI-110 GG GA TT -/+ 
Fe6 β
0
39/β
0
39 GG AG TT -/- 
Fe8 β
0
39/β
0
39 GT AG TT +/- 
Fe9 β
0
39/β
0
39 GG GG TT -/+ 
Fe13 β
0
39/β
0
39 GT AG TC -/- 
Fe15 β
0
39/β
0
39 GT GA TC -/- 
Fe23 β
+
IVSI-110/β
0
IVSI-1 GG AA TC -/- 
Fe24 β
+
IVSI-110/β
+
IVSI-110 GG GG TT -/- 
Fe25=Fe49 β
+
IVSI-110/β
+
IVSI-110 GG AA TC -/- 
Fe28 β
0
39/β
0
44 GT GA TC -/+ 
Fe34 β
+
IVSI-110/β
0
39 GT GA TT -/+ 
Fe35 β
+
IVSI-110/β
+
IVSI-110 GG AA TC -/- 
Fe37 β
+
IVSI-110/β
+
IVSI-110 GG AG TT +/- 
Fe38 β
+
IVSI-6/β
+
IVSI-6 GG AA TC -/- 
Fe42 β
+
IVSI-110/β
0
39 GG GG TT -/- 
Fe43 β
+
IVSI-6/β
+
IVSI-110 GT AG TC -/- 
Fe46 β
0
39/β
0
39 GT AG TT -/- 
Fe52 β
+
IVSI-110/β
+
IVSI-110 GG GA TC -/- 
Fe57 β
+
IVSI-6/β
+
IVSI-6 GG AA TT -/- 
Fe64 HbS/β
0
39 GG AA TC -/- 
Fe67 HbS/β
+
IVSI-6 GG GA TT -/- 
Fe69 HbS/HbS GG GA TT -/- 
Fe73 β
0
39/β
0
39 GG GG TC +/- 
Fe75 HbS/β
+
IVSI-110 GG AG TT -/- 
Fe78 HbS/β
0
IVSI-1 GG AA TC -/- 
Fe80 β
+
IVSI-110/β
0
39 GG AG TC -/- 
Fe81 HbS/HbS GG AA TT -/- 
Fe82 HbS/β
0
IVSI-1 GG AG TC -/- 
AVLTA β
+
IVSI-6/β
0
39 GG AA TT -/- 
AVLTC β
0
39/β
+
5’UTR+20nt GT AG TT -/- 
AVLTD β
+
IVSI-110/β
0
39 GG AG TT -/- 
AVLTE β
+
IVSI-110/β
0
39 GT AA TC -/- 
AVLTF β
0
39/β
0
39 GT AA TC +/- 
AVLTG β
+
IVSI-110/β
0
39 GG AG TC -/- 
AVLTH β
0
39/β
0
39 GG AG TT -/- 
AVLTI=Fe10 β
+
IVSI-6/β
0
39 GG AA TT -/- 
AVLTL β
+
IVSI-6/β
0
39 GG AA TT -/- 
AVLTM β
0
39/β
0
39 GG AG TT +/+ 
AVLTN β
+
IVSI-110/β
0
39 GT AA TC -/- 
AVLTO β
0
39/β
0
28(+C) GT AA TT -/- 
AVLTP β
0
39/β
0
39 GT AG TC -/- 
AVLTQ β
+
IVSI-6/β
0
39 GG AG TT -/- 
AVLTR β
0
39/β
0
39 GG AA TC -/- 
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AVLTS β
0
39/β
0
39 GG AG TC -/- 
AVLTT β
0
39/β
0
39 GG AG TC -/- 
AVLTU β
0
39/β
0
39 GG AA TT -/- 
AVLTV β
+
IVSI-110/β
+
IVSI-110 GG AG TC -/- 
AVLT21 β
0
39/β
0
39 GG AA CC -/- 
AVLT22 β
+
IVSI-110/β
0
39 GG AG TT -/- 
AVLT23 β
+
IVSI-110/β
0
39 GG GA CC -/- 
AVLT24=Fe29 β
0
39/β
0
39 TT AA TT -/+  
AVLT25 β
0
39/β
0
39 GG AA TT -/- 
AVLT27=Fe50 β
0
39/β
0
39 GG GA TT -/- 
AVLT28 β
+
IVSI-110/β
0
39 GG GA TT -/- 
AVLT29 β
+
IVSI-110/β
0
39 GT AA TT -/- 
AVLT31 β
+
IVSI-110/β
0
39 GT GA TC -/- 
AVLT32 β
0
39/β
0
39 GG GA TT -/+ 
AVLT33 β
0
39/β
0
39 GT AA TC -/- 
AVLT34 β
+
IVSI-110/β
0
39 GG AG TC -/- 
AVLT35 β
+
IVSI-110/β
0
39 GG GG TC -/- 
AVLT36 β
+
IVSI-110/β
0
39 GG AG TT -/- 
AVLT37 β
0
39/β
0
39 GT AA TT -/- 
AVLT39 β
+
IVSI-110/β
+
IVSI-110 GG AG TT -/- 
AVLT40 β
+
IVSI-110/β
0
39 GG AG TC -/- 
dZC wt/wt nd nd nd nd 
dPL wt/wt nd nd nd nd 
dRoMuLu wt/wt nd nd nd nd 
dRoDeAA wt/wt nd nd nd nd 
dRoDaCr wt/wt nd nd nd nd 
dGiAg wt/wt nd nd nd nd 
dTG wt/wt nd nd nd nd 
dPF wt/wt nd nd nd nd 
dLePe wt/wt nd nd nd nd 
dNB wt/wt nd nd nd nd 
dLCC wt/wt nd nd nd nd 
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